Lawrence Berkeley National Laboratory

LBL Publications

Title

Modeling Host-Pathogen Interactions in the Context of the Microenvironment: Three-Dimensional Cell Culture Comes of Age

Permalink

https://escholarship.org/uc/item/6cr0589z

Journal

Infection and Immunity, 86(11)

ISSN

0019-9567

Authors

Barrila, Jennifer

Crabbé, Aurélie

Yang, Jiseon

et al.

Publication Date

2018-11-01

DOI

10.1128/iai.00282-18

Peer reviewed

eScholarship.org Powered by the California Digital Library

University of California

IAI Accepted Manuscript Posted Online 4 September 2018
Infect. Immun. doi:10.1128/IAI.00282-18
This is a work of the U.S. Government and is not subject to copyright protection in the United States.
Foreign copyrights may apply.

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

1

2 **Modeling Host-Pathogen Interactions in the Context of the Microenvironment:**

3 **3-D Cell Culture Comes of Age**

4

5 Jennifer Barrila[1], Aurélie Crabbé[2], Jiseon Yang[1], Karla Franco[1], Seth D. Nydam[1],

6 Rebecca J. Forsyth[1†], Richard R. Davis[1], Sandhya Gangaraju[1], C. Mark Ott[3],

7 Carolyn B. Coyne[4], Mina J. Bissell[5], and Cheryl A. Nickerson[1,6*]

8

9 [1]Center for Immunotherapy, Vaccines and Virotherapy

10 The Biodesign Institute, Arizona State University

11 Tempe, AZ, USA

12

13 [2]Laboratory of Pharmaceutical Microbiology

14 Ghent University

15 Ghent, Belgium

16

17 [3]Biomedical Research and Environmental Sciences Division

18 NASA Johnson Space Center,

19 Houston, TX USA

20

21 [4]Department of Pediatrics,

22 University of Pittsburgh,

23 Pittsburgh, PA USA

24

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

25 [5] Division Biological Systems and Engineering,
26 Lawrence Berkeley National Laboratory,
27 Berkeley, CA, USA.
28
29 [6]School of Life Sciences
30 Arizona State University
31 Tempe, AZ, USA
32
33 † Passed away on October 15, 2017

34

35 Running Head: Host-Microbe Interactions: 3-D Cell Culture

36

37 *Address correspondence to Cheryl A. Nickerson, Cheryl.Nickerson@asu.edu

38

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

39 **Abstract**

40 Tissues and organs provide the structural and biochemical landscapes upon which microbial
41 pathogens and commensals function to regulate health and disease. While flat two-dimensional
42 (2-D) monolayers composed of a single cell type have provided important insight into
43 understanding host-pathogen interactions and infectious disease mechanisms, these
44 reductionist models lack many essential features present in the native host microenvironment
45 that are known to regulate infection, including three-dimensional (3-D) architecture, multicellular
46 complexity, commensal microbiota, gas exchange and nutrient gradients, and physiologically
47 relevant biomechanical forces (e.g., fluid shear, stretch, compression). A major challenge in
48 tissue engineering for infectious disease research is recreating this dynamic 3-D
49 microenvironment (biological, chemical, physical/mechanical) to more accurately model the
50 initiation and progression of host-pathogen interactions in the laboratory. Here we review select
51 3-D models of human intestinal mucosa, which represent a major portal of entry for infectious
52 pathogens and an important niche for commensal microbiota. We highlight seminal studies that
53 have used these models to interrogate host-pathogen interactions and infectious disease
54 mechanisms, and we present this literature in the appropriate historical context. Models
55 discussed include 3-D organotypic cultures engineered in the Rotating Wall Vessel (RWV)
56 bioreactor, extracellular matrix (ECM)-embedded/organoid models and organ-on-a-chip (OAC)
57 models. Collectively, these technologies are providing a more physiologically relevant and
58 predictive framework for investigating infectious disease mechanisms and antimicrobial
59 therapies at the intersection of the host, microbe and their local microenvironments.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

Introduction

Mucosal surfaces lining the gastrointestinal, respiratory and urogenital tracts continuously interface with the external environment and serve as a barrier against pathogens, commensals, chemicals, drugs and toxins. These tissues possess a complex architecture with multiple cell types organized into 3-D structures that facilitate tissue-specific functions. The biological, chemical, and biomechanical characteristics that define microenvironmental niches along these surfaces provide the structure and context upon which infection takes place. Pathogens have adapted to detect specific host structures, polarity, and changes in local environmental stimuli (pH, temperature, oxygen, nutrients, hormones, physical forces, etc.) to know where and when to activate specific virulence programs during different infection stages (1-7). A major challenge in tissue engineering for infectious disease research is recreating *in vivo* spatiotemporal properties of dynamic 3-D microenvironments to more accurately model host-pathogen interactions in the laboratory.

Historically, infectious disease has been commonly studied *in vitro* by assessing the interaction of a single microbe with a single host cell type, with the latter grown as flat 2-D monolayers. This reductionist approach has enabled important discoveries and advanced our understanding of mechanisms that underlie infection and disease. However, the study of disease in isolation or out of context can change the native behavior of both host and microbe, thus creating a barrier for researchers to correlate *in vitro* and *in vivo* responses. In this data-rich period where multiple -omics technologies are being synergistically applied for unparalleled insight into host-pathogen interactions, it is critical to consider the context under which these investigations are performed. Reconstructing host microenvironments is key, including 3-D tissue architecture, multicellular complexity, microbiota composition/localization, oxygen tension, transport processes and biomechanical forces (e.g., fluid shear, stretch, compression) (1, 8-11). Within this context, *in vitro* models are positioned along a continuum between 2-D and 3-D, with flat monolayers of a

Infection and Immunity IAI Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

Infection and Immunity

IAI

86 single cell type representing the most basic system with more complex models located further
87 down the spectrum that recreate multiple aspects of the native tissue microenvironment (**Fig. 1**).
88 Since tissues and organs function in a 3-D context, consideration of proper structure is essential
89 for development of models that better mimic *in vivo* responses. Since no current *in vitro* model
90 fully accomplishes this task, multidisciplinary teams of biologists, engineers, physicists,
91 mathematicians and clinicians are creatively working together to develop next-generation 3-D
92 models with enhanced predictive capabilities to open new avenues for clinical translation.
93
94 Present-day 3-D culture techniques result from a series of progressive advances in tissue
95 engineering over the past century to better mimic the native structure and microenvironment of
96 normal and diseased tissues (reviewed in (12)). Indeed, long ago the cancer research
97 community recognized that appropriate modeling of the 3-D microenvironment is important for
98 mimicking disease, leading to development and application of 3-D organoid models developed
99 within or on top of extracellular matrix (ECM) (12-16). The bidirectional exchange of biological
100 and physical signals between cells and their microenvironment regulates cell structure/function
101 and is largely manifested by tensile connections between ECM, cell surface receptors (e.g.,
102 integrins), and the cytoskeleton to transduce signals to and from the nucleus (17-31). This same
103 structural network is also engaged by certain invasive pathogens (e.g., *Salmonella*, *Shigella*,
104 *Listeria*, rotavirus, influenza virus) that hijack and remodel host cell architecture to facilitate their
105 internalization, intracellular trafficking, and/or dissemination (9, 32-34). Similarly, we and others
106 have demonstrated that bacteria also respond to biomechanical forces like fluid shear, which
107 can regulate virulence, gene expression and/or stress responses (1-5, 35-47). Indeed, the
108 discovery of biomechanical forces as environmental regulators of microbial pathogenesis was
109 made by our team almost two decades ago with the discovery that fluid shear forces globally
110 reprogram *Salmonella* gene expression, stress responses and virulence (35). Fluid shear also
111 plays a central role in regulating a number of host responses, including differentiation (48-50).

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

112

113 Although 3-D models have long been applied for cancer research (12-16), their utility remained
114 largely unincorporated by the infectious disease community until the late 1990s and early
115 2000s. As expected for many new ideas in an established field, the use of 3-D models to study
116 host-pathogen interactions was initially met with skepticism. The first reports of 3-D models to
117 study viral infections were by Long et al. in 1998 (rhinovirus) and bacterial infections by
118 Nickerson et al. in 2001 (*Salmonella enterica* serovar Typhimurium/*S*. Typhimurium) (11, 51).
119 Recently, infectious disease researchers have broadly embraced 3-D models for studying
120 pathogenesis mechanisms, biomarker discovery, and drug candidate screening. In this review,
121 we highlight key microenvironmental factors to consider when selecting *in vitro* 3-D intestinal
122 models to study host-pathogen interactions. We focus on three key technologies for model
123 development, 1) the RWV bioreactor, 2) ECM-embedded/organoid models, and 3) gut-on-a-chip
124 models, and propose a vision for future model advancements. We also provide proper historical
125 context for use of 3-D cell cultures in studying host-pathogen interactions, which is finally
126 gaining a critical mass of scientists who understand and appreciate the value of studying
127 disease in the proper context of tissue form and function.

128

129 I. Microenvironmental cues in host-microbe interactions

130 Mucosal tissue function and homeostasis are meticulously controlled by complex bidirectional
131 interactions between cells and their microenvironment (15, 20, 25, 27-29, 52-55). The
132 microenvironment includes 3-D tissue architecture, multiple cell types, ECM , innate immunity
133 mediators, indigenous microbiota, and physical forces. These factors are regulatory signals for
134 mucosal pathogens and may be beneficial or detrimental for infection (1-5, 8, 35-45, 47, 56-64).
135 Below we address key cellular, biochemical and biophysical cues that dictate infection outcome
136 and are important considerations when modeling host-enteric pathogen interactions.

137

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

138 **Cellular factors.** Intestinal mucosal epithelium contains an array of specialized epithelial and
139 immune cells that work in synergy to protect against infection by: (i) serving as a barrier against
140 luminal toxins, commensals and pathogens, (ii) sampling microbial antigens, and (iii) recruiting
141 innate and adaptive immune effectors (65). The intestine contains multiple epithelial cell types,
142 including enterocytes (absorptive functions), enteroendocrine cells (hormone secretion), Paneth
143 cells (antimicrobial production), goblet cells (mucin production), M cells (luminal antigen
144 sampling/induction of mucosal immunity), Tuft cells (Th2 immunity), and Cup cells (unknown
145 function) (66, 67). The intestine also contains immune cells for innate and adaptive responses to
146 pathogen attack, including macrophages, dendritic cells, T and B cells, including those
147 organized in lymphoid structures termed Peyer's patches, sites of induction of mucosal
148 immunity. As the body's largest immune organ, the composition, organization and function of
149 the intestine varies by region and consists of integrated cross-communication networks of
150 different cell types and effectors critical for protection against pathogens (described in (65, 68-
151 73)).
152
153 Epithelial cell polarity establishes barrier function, regulates uptake/transport of nutrients, and
154 maintains epithelial architecture (65, 74-76). In the intestine, apical surfaces face the lumen and
155 regions between villi/folds, lateral surfaces face adjacent cells, and basal surfaces face the
156 basement membrane and lamina propria. Along Peyer's patches and isolated lymphoid follicles,
157 the basal side of the follicle-associated epithelium overlies a subepithelial dome region
158 containing a mixture of immune cells (77). The distinct biochemical composition (e.g., protein,
159 lipid) of apical and basolateral surfaces facilitates their specific functions (76). Given that many
160 pathogens have evolved to recognize surface-specific molecules for attachment and/or to
161 disrupt barrier integrity to enable their uptake and dissemination (6, 75, 78-80), appropriately
162 modeling polarity *in vitro* is critical as pathogens infect host cells differently depending on
163 whether they are polarized or non-polarized (81-84). Maintaining barrier integrity requires proper

Accepted Manuscript Posted Online

164 expression and localization of tight and adherens junctions. Adherens junctions are mediated by
165 E-cadherin and catenin interactions, while tight junctions are composed of transmembrane
166 proteins (e.g., claudins, occludins) and cytoplasmic plaque proteins (e.g., zonula occludens).
167 While generally protective, junctional complexes are also exploited by pathogens to facilitate
168 invasion (75) and some enteric viruses utilize receptors localized to these junctions (78, 79).
169
170 Another major cellular component encountered by enteric pathogens is the diverse microbial
171 community – termed microbiota (referring to microorganisms) or microbiome (referring to
172 microbial genomes). The intestinal tract contains prokaryotes, viruses, archaea, and eukaryotes,
173 some of which protect the host against pathogen colonization by a variety of mechanisms,
174 including epithelial cell turnover, mucin synthesis, and triggering bacterial sensors on host cells
175 (85-87). Reciprocal interactions between host and microbiota contribute to tissue function and
176 homeostasis and determine microbiota composition, thereby playing an important role in
177 infection and disease (88). For example, intestinal microbiota regulate production of
178 antimicrobial peptides by Paneth cells (89) and shape immune responses by regulating
179 numbers, subsets, and/or functions of T, B and myeloid cells (65). Microbiota-induced changes
180 in immunity also determine intestinal microbiota composition (86, 90).
181
182 The intestinal microbiota is comprised of ~10^{14} bacteria (>1000 species), with Firmicutes and
183 Bacteroidetes most abundant (91-94). Interpersonal variation in intestinal microbiome occurs,
184 with each individual carrying a subset of the total known microbiome (95). Temporal and spatial
185 variation occurs throughout the intestinal tract (96, 97). Increasing data suggest a relationship
186 between an imbalanced intestinal microbiome and various diseases, including obesity,
187 inflammatory bowel disorders and cancer (98). The importance of gut microbiota to health is
188 highlighted by successful clinical application of fecal microbiota transplants from healthy

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

IAI Infection and Immunity

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

189 individuals to patients with recurrent, antibiotic resistant *Clostridioides difficile* (*C. difficile*) (99-
190 101).
191
192 **Biochemical cues.** Mucosal tissues contain an array of small molecules, including innate
193 defense mediators that target pathogens and regulate downstream host defenses. Intestinal
194 mucus harbors compounds from the innate and adaptive systems that protect against microbial
195 insult, including digestive enzymes (e.g., lysozyme), lactoferrin, antimicrobial peptides,
196 complement, and antibodies (e.g., secretory immunoglobulin A/sIgA) (65). In addition, cells of
197 the innate defense system respond to pathogen-associated molecular patterns (PAMPs) using
198 pathogen recognition receptors (PRRs). Depending on the pathogen, PRR-mediated signal
199 transduction results in different cellular outcomes (e.g., cell proliferation, apoptosis, antimicrobial
200 peptide production, autophagy, cytokine secretion). Cytokine production leads to recruitment of
201 innate and adaptive immune effectors to the infection site, representing a bridge between these
202 two arms of immunity (65, 102).
203
204 Mucins are complex mixtures of high molecular weight, glycosylated macromolecules that bind
205 and remove pathogens and their products (7, 102). Enteric pathogens sense and respond to
206 cues within mucus and overcome this barrier to reach underlying epithelium (7). Normal
207 intestinal mucus consists of two layers: an outer layer colonized by microbes and a sterile inner
208 layer (103-105). The composition and thickness of these mucin layers varies throughout
209 intestinal regions to accommodate their different functions and microbial burdens. Within the
210 small intestine the inner and outer mucosal layers are thinner to facilitate nutrient absorption,
211 with thicker regions found towards the ileum where microbial burden is heavier (7). In the colon,
212 both layers are thicker to accommodate the burden of several trillion commensals (7). The
213 presence of sIgA and other mucin antimicrobials also serves to reduce bacterial colonization
214 (106).

Accepted Manuscript Posted Online
Infection and Immunity
IAI
Infection and Immunity

215

216 The ECM is another key contributor to tissue homeostasis. Historically neglected as a signaling
217 entity, seminal discoveries have revealed the central role of ECM in regulating tissue
218 architecture/function (20, 53). The ECM is a three-dimensional non-cellular scaffold comprised
219 of proteins (e.g., collagens, elastins, laminins, fibronectins), proteoglycans and water. Two main
220 types of ECM include: (i) interstitial connective tissue matrix, which serves as a cellular scaffold,
221 and (ii) basement membrane matrix, which separates epithelium from interstitium (107, 108).
222 ECM components also serve as ligands for cell receptors like integrins, which transduce
223 physical forces into biological responses (mechanotransduction). Additionally, immune
224 responses are mediated through interactions with the ECM (108, 109). Furthermore, the ECM
225 controls availability/release of growth factors and other signaling molecules (hormones,
226 cytokines) (108). The complexity, composition and structure of ECM are highly dynamic and
227 specific (as are the biochemical gradients it contains) and depend on tissue type, developmental
228 stage, and health/disease state (108).

229

230 **Biophysical forces.** The role of physical forces in cell and tissue development/function is as
231 important as those of genes and biochemical signals (28, 110). Physical forces regulate cell
232 proliferation, differentiation and homeostasis (111, 112). Forces experienced by intestinal cells
233 include fluid shear, pressure (113), and contractile peristalsis of muscles (114). Hydrodynamic
234 calculations suggest that fluid shear forces on the exposed epithelial brush border microvilli are
235 ~ 200 times greater than those between microvilli (< 0.01 dynes/cm^2) (115).

236

237 The cytoskeleton and its linkage with ECM play an essential role in enabling cells to sense and
238 respond to biophysical forces. While the governing role of ECM as a dynamic signaling entity
239 that regulates tissue form/function is now appreciated, it was initially considered a purely static
240 scaffold. However, tissue-specific architecture and function are regulated by the biophysical

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

241 properties of ECM (20, 116, 117), which exerts physical influences transduced by cell surface
242 receptors through the cytoskeleton to the nucleus to ultimately alter cellular and molecular
243 properties. These structural networks are critical for regulating cell shape/architecture, and have
244 been modeled using the principle of tensegrity, which refers to structures that are stabilized
245 under continuous tension by balancing opposing tension and compression forces (27-29, 31).
246 The integration of biophysical forces across cells and tissues using this structural network
247 regulates a wide range of biological processes (e.g., cell proliferation, apoptosis, differentiation,
248 adhesion, migration, gene expression, architecture)(8, 20, 21, 23, 25, 27, 29-31, 55, 118).
249 Accordingly, ECM composition and stiffness are critical regulators of cellular responses (119,
250 120). These properties are continuously remodeled through the process of “dynamic reciprocity”
251 (17, 20, 53, 118), theorized by Bissell in 1982 to explain how signaling between the ECM and
252 nucleus regulate tissue function. This laid the foundation for modern 3-D cell culture approaches
253 used today (20, 108, 121). Not surprisingly, pathogen-ECM interactions play an important role in
254 mediating infection (122-127). In addition to impacting the host, physical forces also globally
255 alter bacterial gene expression, stress responses, and virulence in unexpected ways to
256 contribute to infection (5, 36-40, 47, 62-64).
257

258 **II. Modeling the microenvironment: 3-D models for infectious disease**

259 Several cell culture systems exist for the development and application of 3-D models of human
260 tissues for infectious disease research, including the RWV bioreactor, ECM-embedded scaffolds
261 (e.g., ECM extracts, purified ECM, or synthetic/semi-synthetic hydrogels), and organ-on-a-chip
262 (OAC) models. The choice of system to use depends on several factors, including the
263 experimental question being addressed, technical complexity, and cost and expertise for model
264 development. Different cell types in the native tissue (including immune cells) can be co-
265 cultured in these models to further enhance physiological relevance. Additionally, a single
266 epithelial cell type can spontaneously differentiate into multiple epithelial cell types normally

Accepted Manuscript Posted Online

267 found in the parental tissue and undergo self-assembly into tissue-like structures using all of
268 these 3-D technologies. To date, most *in vitro* infection studies have been performed using cell
269 lines; however, there is a push to develop models using either primary and/or stem cells to
270 better mimic the native tissue. To explore the integration of different environmental signals in
271 regulating infection, a hierarchical series of increasingly complex 3-D model systems comprised
272 of different cells types can be developed and applied in parallel under differing experimental
273 conditions (e.g., different oxygen tensions, physical forces).
274
275 **RWV-derived 3-D models.** The RWV bioreactor is an optimized form of suspension culture that
276 facilitates formation of self-organizing 3-D tissue-like aggregates by allowing cells the spatial
277 freedom to co-localize and self-assemble based on natural affinities within a low fluid shear
278 environment (**Fig. 1B, panel a**) (8, 128). Fluid shear influences cell proliferation, differentiation,
279 morphology and function (30, 115, 129-141). Models developed within the dynamic RWV
280 environment experience excellent mass transfer of nutrients/wastes and exhibit enhanced
281 structure, differentiation, function, and multicellular complexity relative to 2-D monolayers (11,
282 81, 142-155). Along these lines, observations from the 1970s showed that flotation of collagen
283 gels led to a more permissive environment for cellular differentiation (12, 156, 157). Moreover,
284 the low fluid shear environment in the RWV is also physiologically relevant to that encountered
285 by pathogens in low shear regions of the infected host, including intestine (38, 115, 130-132).
286 Accordingly, the RWV is also used to culture pathogens to study the role of fluid shear and
287 mechanotransduction in regulating microbial pathogenesis and host-pathogen/commensal
288 interactions (1, 35-41, 45-47, 62, 64, 146, 158-168).
289
290 The RWV is among the most extensively used approaches to develop 3-D models to study host-
291 pathogen interactions. It was the first technology used to develop 3-D models for infection
292 studies with bacterial (*Salmonella*) and viral (rhinovirus) pathogens (11, 51). A range of RWV-

Infection and Immunity IAI Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

293 derived 3-D models have been developed using cell lines, stem cells, and/or primary cells,
294 including small and large intestine (11, 81, 142, 144, 146, 147, 153, 169-178), lung (145, 148,
295 179-183), liver (149, 154, 175, 184, 185), bladder (8, 186-188), reproductive tissues (150-152,
296 189-191), heart (192-194), prostate (143, 187, 195), pancreas (196, 197), nervous tissue (183,
297 198-200), blood-brain barrier (201), skin (202), eye (203), bone, joint or disc (204-208) and
298 tonsil (209), among others. These studies demonstrated that RWV-derived models exhibit
299 enhanced *in vivo*-like characteristics, including: spontaneous differentiation into multiple cell
300 types that self-organize into 3-D structures (**Fig. 1B, panel d**), polarization, appropriate
301 expression/localization of adherens/tight junctional complexes, metabolic product secretion,
302 gene expression, cytokine production, responses to antimicrobials and microbial products,
303 support of commensals, and/or susceptibility to infection (8, 11, 81, 142-154, 169-195, 198-
304 209). In addition, RWV models have been advanced to incorporate immune cells to study their
305 role in host-microbe interactions (172, 176, 178, 181).
306
307 Models are typically initiated by harvesting monolayers, combining cells with porous ECM-
308 coated microcarrier scaffolds and loaded into the RWV. Scaffold and ECM porosity allow the
309 basal side of cells to experience autocrine/paracrine communications, aiding cellular
310 differentiation/responses in a manner reflecting *in vivo* tissues. This differs from monolayers
311 where cells proliferate on impermeable surfaces, thus hindering proper communications across
312 apical and basolateral surfaces. Additionally, models may be developed scaffold-free or using
313 non-microcarrier scaffolds (e.g., decellularized tissues) for transplantation (180, 182, 210). Once
314 developed, distribution of 3-D models into multi-well plates lends to their experimental
315 tractability for infection assays, as their structural/functional integrity remains intact following
316 seeding. Alternatively, pathogens or compounds can be directly added to the RWV to study
317 interactions under physiological fluid shear. One key advantage of RWV culture is the

IAI Infection and Immunity

Accepted Manuscript Posted Online

318 production of large numbers of cells (~10^7-10^8 per culture). Below we discuss RWV-derived 3-D
319 models of human intestinal mucosa.
320
321 *RWV-derived intestinal models.* We began using the RWV to engineer 3-D models of human
322 intestine for infection studies in the late 1990s after realizing that available models for studying
323 bacterial pathogenesis lacked multiple aspects of the *in vivo* microenvironment (11). RWV-
324 derived 3-D models have enabled the study of host-microbe interactions relevant to different
325 regions of the intestinal tract, including small intestine (11, 170) and colon (81, 144, 146, 147,
326 153, 172, 173, 176, 178). Imaging of these models revealed enhanced 3-D architecture relative
327 to monolayers, including the presence of extensive 3-D folds and microvilli, that more closely
328 resembled what is observed *in vivo* (**Fig. 1B, panel d**). These 3-D models are essentially
329 "inside-out" such that the apical/luminal side faces the media and the basal side faces the
330 scaffold, allowing for straightforward introduction of pathogens, toxins, and antimicrobials at the
331 apical surface, as commonly occurs *in vivo*. Collectively, these models have shown
332 physiologically relevant expression and localization of key cellular components, including
333 junctional proteins (e.g., ZO-1, occludin, symplekin, E-cadherin, β-catenin, desmosomes),
334 secretion of basal lamina components (e.g., collagen types II, III, IV, laminin, vimentin,
335 fibronectin), brush border formation with villin, and/or mucus secretion (11, 81, 144, 146, 147,
336 153, 170, 172, 173, 176, 178). Spontaneous cellular differentiation into multiple lineages found
337 in the intestinal epithelium is also observed, including enterocytes, M cells, goblet cells, and/or
338 Paneth cells (enteroendocrine cells were not evaluated) (11, 81, 147, 153, 172, 176). The
339 presence of multiple cell types within a model (e.g., epithelial and immune cells) enables study
340 of their combined effects on infection, and in particular, pathogen co-localization patterns with
341 different cell types. An example is described below using an advanced 3-D RWV co-culture
342 model that combined human colonic epithelium with phagocytic macrophages to study infection
343 by different *Salmonella* pathovars (172). Primary human lymphocytes have also been

Infection and Immunity IAI Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online
Infection and Immunity
IAI

344 incorporated in a 3-D co-culture model of intestinal epithelium to study *Salmonella* infection
345 (176).
346
347 RWV-derived intestinal models have contributed to the study of a variety of pathogens such as
348 *S.* Typhimurium (including multidrug resistant ST313), *S.* Typhi, Enteropathogenic *Escherichia*
349 *coli* (EPEC), Enterohemorrhagic *E. coli* (EHEC), *Cryptosporidium parvum*, and human
350 enteroviruses including coxsackievirus B (CVB) and poliovirus (11, 81, 144, 146, 147, 153, 172,
351 173, 176). Studies with *S.* Typhimurium using 3-D models of small and large intestine displayed
352 marked differences from monolayers in colonization, tissue morphology, apoptosis,
353 prostaglandin and cytokine expression (11, 81, 153). The responses of these 3-D intestinal
354 models to *S.* Typhimurium challenge were highly predictive of *in vivo* responses in
355 humans/animals (11, 81, 153), including rapid repair of the small intestine (initial site of
356 *Salmonella* pathogenesis) and significant damage to the colon (primary site of pathogenesis)
357 (211). These models were also the first *in vitro* systems to challenge the widely accepted
358 paradigm established using monolayers that *Salmonella* Pathogenicity Island-1 (SPI-1) Type
359 Three Secretion System (T3SS) is required for invasion of intestinal epithelium (81, 153).
360 Historically, studies with monolayers contradicted *in vivo* observations wherein successful
361 animal infections were possible with T3SS SPI-1 mutants (212, 213), and clinical isolates of
362 *Salmonella* lacking SPI-1 function were isolated from foodborne disease outbreaks in patients
363 experiencing gastroenteritis (214). Using a 3-D intestinal model comprised solely of epithelial
364 cells, Radtke et al. demonstrated that SPI-1 mutants and a *Salmonella* mutant lacking all known
365 T3SS (SPI-1, SPI-2, and the flagellar system) still exhibited high levels of invasion relative to
366 wild type (although approximately 0.5-1 log lower) (153). As expected, in monolayers these
367 mutants exhibited little-to-no invasion (<10 CFU); a finding which does not reflect *in vivo*
368 observations (153). Thus for the first time, an *in vitro* intestinal epithelial model was able to
369 parallel *in vivo* results by supporting *Salmonella* invasion independently of SPI-1. These findings

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest
Infection and Immunity

Accepted Manuscript Posted Online

Infection and Immunity

IAI

370 demonstrate the enhanced capability of RWV models to predict *in vivo*-like pathogenic
371 mechanisms.
372
373 Host-pathogen-commensal and host-commensal interactions have also been investigated using
374 RWV 3-D intestinal models (173, 178). Commensal microbes naturally enhance intestinal
375 mucosal barrier function against pathogen colonization through complex mechanisms not yet
376 fully characterized (215). Naturally occurring probiotic strains of bacteria are being exploited as
377 a strategy against pathogens to combat ongoing problems of antibiotic resistance. Treatment of
378 a 3-D intestinal model with *Lactobacillus reuteri* or its antimicrobial metabolite, reuterin, before
379 or after challenge with *S*. Typhimurium reduced adhesion, invasion and intracellular survival of
380 this pathogen as compared to untreated cells (173). This was the first study to report the effect
381 of reuterin on the enteric infection process for any mammalian cell type. A 3-D intestinal co-
382 culture model containing immune cells was used to profile responses to both free secretory IgA
383 (SIgA) and SIgA complexed with a commensal strain of *E. coli* (178). Application of free SIgA to
384 the model induced upregulation of MUC2, IL-8, and polymeric immunoglobulin receptor (pIgR),
385 secretion. When SIgA was complexed with *E. coli* and applied to the model, these responses
386 were down-regulated relative to models treated with free SIgA.
387
388 Barrila and Yang et al. reported advancement of a 3-D HT-29 colon model to include phagocytic
389 macrophages, thereby improving its physiological relevance to study aspects of the innate
390 immune response to infection (172). Characterization of this co-culture model revealed
391 macrophages integrated between and underneath epithelial cells, while preserving epithelial
392 tight junctions and presence of multiple epithelial cell types, including enterocytes, M cells and
393 goblet cells (172). Macrophage phagocytosis was confirmed by evaluating their ability to engulf
394 inert, bacteria-sized beads. Contribution of macrophages to *Salmonella* infection was assessed
395 using *S. enterica* pathovars with differing host tropisms and disease phenotypes, including the

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity

Accepted Manuscript Posted Online

396 well-studied sequence type ST19 Typhimurium strain SL1344, which causes disease in a wide
397 range of hosts, the multi-drug resistant ST313 Typhimurium strain D23580, and the human-
398 specific *S.* Typhi strain Ty2. Although classified as Typhimurium, ST313 strains display genome
399 degradation similar to human-adapted Typhi, and are associated with devastating epidemics of
400 blood-borne infections in sub-Saharan Africa (216). Bacteria were cultured aerobically or
401 microaerobically prior to infection to simulate oxygen environments encountered before and
402 during intestinal infection. Colonization of all strains was reduced in the co-culture model
403 containing macrophages relative to the epithelial model, indicating antimicrobial function of
404 macrophages. Although ST313 are considered 'highly invasive' due to the systemic infection
405 they cause, D23580 was not highly invasive in the 3-D models, but instead exhibited enhanced
406 survival/replication, thus providing clues as to what drives their pathogenicity. Pathovar- and
407 oxygen-specific differences in host cell co-localization patterns were also observed (**Fig. 1B,**
408 **panel g**), indicating the ability of these advanced models to distinguish between closely related
409 *Salmonella* serovars, thus providing a unique advantage over models composed of a single cell
410 type (172).
411
412 RWV-derived intestinal models are also valuable for investigating host-pathogen interactions for
413 which conventional cultivation strategies are unable to adequately model *in vivo* complexity.
414 Recently, a 3-D colonic model was applied to study human CVB (147); a pathogen for which *in*
415 *vitro* and *in vivo* models may not fully model the enteral infection route in humans (147, 217-
416 220). Comparisons between polarized 2-D and 3-D cells revealed that the 3-D model displayed
417 an enhanced number of viral particles secreted into the media at early stages of the viral life
418 cycle, which did not coincide with increased host cell destruction relative to monolayers (147).
419 These data suggest that 3-D models exhibit an enhancement in non-lytic release of viral
420 particles, which might result from morphological changes (e.g., enhanced brush border
421 formation) in 3-D cells. Similarly, another 3-D colonic model was used to study *Cryptosporidium*

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity
IAI
Infection and Immunity

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

422 *parvum*, a parasite for which there is a lack of physiologically relevant *in vitro* and *in vivo* models
423 (144). Following *C. parvum* infection, morphological changes were observed that were
424 consistent with those from colonic biopsies of infected patients (144). These studies further
425 emphasize the critical importance of model complexity and physiological relevance as
426 determinants in enabling host-pathogen interactions.
427
428 In summary, 3-D RWV intestinal models are powerful tractable research tools that advance the
429 study of host-pathogen interactions. These models can be modularly altered to incorporate
430 different cell types (including patient-derived cells), ECM, commensal microbiota, physical
431 forces, etc, akin to *in vivo* scenarios, increasing their relevance. Their tissue-like architecture,
432 differentiation and polarization, enhanced expression/localization of junctional proteins, and
433 mucin production are necessary components of an effective barrier to invading pathogens.
434
435 *Limitations and future directions of RWV-derived 3-D models*. Although many key
436 structural/functional characteristics of parental tissues have been successfully recapitulated
437 using RWV models, several limitations remain. The full extent of 3-D architecture, multicellular
438 complexity and array of physical forces of *in vivo* tissues has not yet been attained. Ongoing
439 studies are further enhancing these features, plus incorporating patient-specific immune cells
440 and fecal microbiota, and achieving vascularization and innervation. Models can be costly due
441 to high media consumption required for culturing large numbers of cells, however researchers
442 can scale down. Although bead porosity facilitates apical/basal cytokine secretion and there is
443 excellent access to the apical side of the models, there is currently an inability to sample the
444 basal side. This also prevents measurement of transepithelial electrical resistance (TEER),
445 which measures electrical resistance across a monolayer as a proxy for assessing barrier
446 integrity (221). The technique involves using two electrodes, one in contact with cells on a
447 semipermeable membrane (e.g., apical side) and the other in a different chamber containing

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

448 culture medium (e.g., basal side). With most RWV models grown on tiny (~175 μm) microcarrier
449 beads, these measurements are not currently possible with off-the-shelf technology. This
450 challenge will likely be surmounted with custom electrode design to accommodate current RWV
451 models or the use of alternative scaffolds. Currently, immunofluorescence imaging of
452 cytoskeletal and tight junctional markers represents an alternative method to evaluate model
453 integrity. As these models grow in size and complexity, introduction of vasculature and nerve
454 cells will be important. Finally, current models are not easily amenable to chronic infection due
455 to lack of perfusion once removed from the RWV, however inclusion of automated waste
456 removal and nutrient delivery during infection will facilitate this approach.
457
458 **3-D organoid models.** The term organoid ('organ-like') has been used to describe a variety of
459 3-D models that resemble *in vivo* tissues. Historically, this included models engineered with
460 different technologies using cell lines, stem cells, primary cells, or tissue explants either
461 embedded in, or cultured on top of, ECM scaffolds that allow cells to self-assemble into 3-D
462 structures (8, 12, 144, 146, 147, 170, 172, 222-230). Advances in stem cell biology led to a
463 recent terminology shift to more specifically define organoids as 3-D models derived from stem
464 cells, progenitor cells or primary explants (223, 231-239). Herein, we focus on 3-D models
465 cultured within a 3-D ECM matrix that fit this definition. It is important to emphasize that current
466 models are based on decades of work by pioneering cell biologists that laid the foundation for
467 the current organoid field (reviewed in (12)), representing an advancement and merging of old
468 and new technologies to enable novel discoveries (12, 229, 240). Models cultivated using thick
469 ECM matrices have deep roots in tissue engineering and cancer biology, where they were
470 applied to develop advanced models enabling the study of a variety of biological mechanisms,
471 particularly with regards to understanding the interrelationship between tissue structure and
472 function (12). This effort resulted in a critical mass of scientists who now recognize the

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

473 importance of 3-D models for infection and are bringing elegant advances to the field, but may
474 not be fully aware of their historical context.
475
476 A range of different organoid models have been established, including small and large intestine
477 (230, 231, 233, 235, 241-269), lung (270-275), stomach (276-283), breast (55, 284, 285), brain
478 (286-288), liver (223, 289, 290), pancreas (223, 291, 292), gall bladder (293), eye (294), kidney
479 (295), prostate (223, 296, 297) and reproductive tract (298, 299), among others. Relative to
480 monolayers, these models more closely mimic endogenous tissues, including organization and
481 spontaneous differentiation of multiple cell types into physiologically relevant 3-D structures
482 (**Fig. 1B, panel e**), expression and localization of tight junctions, mucus production, polarity,
483 gene expression, cell viability and proliferation, cytokine production, responses to antimicrobials,
484 support of commensals and susceptibility to infection (12, 55, 223, 227, 229-236, 238, 239, 241-
485 267, 270-320).
486
487 To develop 3-D organoid models, stem cells or tissue explants containing stem cells are used.
488 Biopsies may be treated with a dissociation agent and/or mechanically disrupted prior to
489 embedding into ECM. Stem cells isolated from biopsies can be pre-differentiated into progenitor
490 cells and further differentiated into ECM-embedded organoids. Differentiation into committed
491 cell types is enabled by stepwise supplementation and/or removal of signaling factors during
492 culture (250, 252, 253, 255, 265, 276, 279, 304, 321-323). Purified ECM components and
493 mixtures can be used, including Matrigel, a laminin-rich ECM isolated from chondrosarcomas
494 (324, 325). Synthetic hydrogels help circumvent challenges associated with Matrigel, including
495 batch-to-batch variation and potential carcinogenic issues connected with tumor-derived
496 matrices (230).
497

Accepted Manuscript Posted Online
Infection and Immunity
IAI

498 *3-D intestinal organoids.* Sato et. al. (250) and Ootani et al. (254) independently reported
499 conditions enabling long-term *in vitro* culture of mouse intestinal crypts containing Lgr5+ stem
500 cells (as well as purified Lgr5+ stem cells that generate villus-crypt-like structures (250)). These
501 approaches used either Matrigel (250) or collagen (254) in combination with supplementation of
502 Wnt agonist R-spondin1. Sato et al. also included epidermal growth factor to enable crypt
503 growth, and noggin to facilitate passaging (250). These models displayed a polarized,
504 multicellular epithelium (enterocytes, goblet cells, Paneth cells, enteroendocrine cells) organized
505 into a central lumen lined by villus-crypt-like structures (250, 254). Murine intestinal organoids
506 developed from single Lgr5+ stem cells also developed into these multicellular structures (250).
507 Subsequently, additional factors were included to enable human colonoid culture (265).
508
509 The NIH Intestinal Stem Cell Consortium defined a standardized nomenclature to reflect model
510 sources, approaches and *in vitro* structures (326). Structures directly isolated include epithelial
511 sheets, crypts and organoids (crypts and surrounding mesenchymal elements) (326). Various
512 structures produced *in vitro* from small intestine include enterospheres (rounded epithelial cyst-
513 like structures); enteroids (formation of budding crypts from enterospheres); and induced
514 intestinal organoids (multicellular clusters from induced embryonal or pluripotent stem cells;
515 e.g., induced human intestinal organoids) (326). Analogous colonic structures include
516 colonospheres, colonoids and colonic organoids (326). It is common to see terms used
517 interchangeably and the nomenclature will likely evolve as the field expands.
518
519 Model infection can be accomplished by: 1) addition of pathogen directly to the media (basal
520 side), 2) microinjection into the lumen (**Fig. 1B, panel b**), 3) shearing of models followed by
521 pathogen addition, and 4) disruption of 3-D models into flat monolayers followed by pathogen
522 addition (231, 238). Consideration of the normal infection route is critical. Direct addition to the
523 media is easiest; however, for pathogens that infect via the apical/luminal side, this represents a

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest
Infection and Immunity

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

524 non-physiological route of infection. Microinjection is technically challenging, but preferable for
525 pathogens that normally infect from the lumen. Due to challenges associated with
526 microinjection, there is a growing tendency to mechanically dissociate organoids into smaller
527 pieces or completely dissociate into monolayers on Transwell inserts or plastic (238, 262, 282,
528 314, 315). This approach has been successful for a number of studies, including cultivation of
529 norovirus (315), a major advance in the field. Use of Transwell inserts also facilitates TEER
530 analysis and easier cytokine sampling from the apical/luminal side of the model.
531
532 When dissociating 3-D models prior to infection, it is important to note that this disconnects their
533 form and function similar to disrupting primary tissue into monolayers and may render them less
534 predictive for some (not all) phenotypes. In this approach, use of Transwell inserts are
535 preferable over plastic as the former display improved physiological relevance over conventional
536 monolayers (327). Additional profiling should confirm the extent to which the dissociated model
537 may have de-differentiated and additional culture time may be required to re-establish
538 polarity/barrier function. Key findings should be validated using intact organoids and
539 microinjection to avoid artifacts. Additionally, since ECM-pathogen interactions are important for
540 infection dynamics (61), infection surfaces should not contain ECM components not typically
541 found in that location *in vivo* (e.g., lumen) if the pathogen would not normally encounter it.
542
543 A variety of pathogens have been studied using 3-D enteroid/colonoid/organoid models
544 including *Salmonella*, *C. difficile*, EHEC, EPEC, Enterotoxigenic *E. coli* (ETEC), Norovirus,
545 rotavirus, enteroviruses, *Toxoplasma gondii* and Coronaviruses (231, 232, 234-236, 239, 241-
546 246, 258-264, 267, 269, 308-320, 328). The first infection using induced human intestinal
547 organoids (iHIOs) was performed using human rotavirus, which lacks robust *in vitro* culture
548 systems (316). Both laboratory and clinical rotaviruses replicated in iHIOs and were detected in
549 epithelial and mesenchymal cells (316). Crypt-derived enteroids also supported rotavirus

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

550 replication and were used to assess antiviral efficacy against patient isolates (245, 267).
551 Ettayebi et al. made a significant advance by the successful *in vitro* culture of human norovirus
552 (HuNoV), known for its lack of a reproducible culture system (315). The authors initially cultured
553 3-D intestinal organoids and then dissociated them into monolayers on plastic or Transwell
554 inserts (315). Successful viral replication was observed and only enterocytes were infected with
555 HuNoVs regardless of strain or intestinal region from which the model was derived. Additional
556 viral models including those using enteroviruses (e.g., CVB, Echovirus 11, and Enterovirus 71)
557 have identified the cell type-specific nature of these infections and the virus-specific nature of
558 innate immune signaling in response to infection (328).
559
560 Enteroid models were also used to study *S.* Typhimurium and *E. coli*. Zhang et al. (241) and
561 Wilson et al. (244) used crypt-derived enteroids to study *Salmonella* infection. *S*. Typhimurium
562 successfully colonized the model (241, 244) and infection responses aligned well with *in vivo*
563 observations, including disruption of tight junctions, inflammatory responses, and decreased
564 stem cell numbers (241). Forbester et al. infected iHIOs with *S*. Typhimurium and observed
565 physiological transcriptomic and cytokine profiles (258). Injection of *E. coli* O157:H7 into iHIOs
566 containing neutrophils led to loss of actin, epithelial integrity disruption, induction of
567 inflammatory cytokines, and neutrophil recruitment (**Fig. 1B, panel h**) (261). In contrast,
568 commensal *E. coli* was retained within the lumen with no loss of model integrity. Infection of
569 colonoid-derived Transwell models identified MUC2 and protocadherin-24 as early EHEC
570 infection targets (262). Colonoids were initially cultured in 3-D followed by dissociation onto
571 Transwells. Model differentiation correlated with expression of differentiation markers, increased
572 TEER, and microvilli (262). EHEC preferentially colonized the differentiated model relative to an
573 undifferentiated control, reducing colonic mucus and inducing microvilli damage. A similar
574 approach was applied to study EPEC and ETEC infections in co-culture models containing
575 macrophages (314). Inclusion of macrophages in the bottom chamber of the enteroid-derived

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

576 Transwell model enhanced barrier function, increased epithelial height, and altered cytokine
577 responses relative to the control. EPEC increased total macrophage numbers and induced
578 projections that extended into the epithelium, while ETEC induced macrophage extensions
579 across the epithelium to the apical surface. Presence of macrophages in the co-culture model
580 enhanced barrier function and correlated with decreased numbers of ETEC relative to the model
581 lacking immune cells.
582
583 iHIOs were also used to study *C. difficile* infection (CDI) (259, 260, 263, 264). CDI patients
584 secrete acidic mucus consisting primarily of MUC1, with decreased MUC2 and altered
585 oligosaccharide composition relative to healthy patients (260). Injection of the pathogen alone
586 into iHIOs decreased MUC2, while whole CDI stool supernatant was required to induce patient-
587 like oligosaccharide composition changes (260). iHIOs were also used to investigate non-
588 toxigenic and toxigenic strains of *C. difficile* and purified toxins, TcdA and TcdB (263). Injection
589 of the toxigenic isolate or purified TcdA led to loss of barrier function, while iHIOs injected with
590 the non-toxigenic strain remained intact. Separately, colonoids helped identify Frizzled proteins
591 as receptors for the TcdB toxin (264).
592
593 In summary, 3-D organoid models are advancing mechanistic understanding of host-microbe
594 interactions due to their enhanced 3-D architecture, presence of $Lgr5^{+}$ stem cells together with
595 multiple cell types and other functional properties. In addition, patient organoid 'biobanks' have
596 been established and are facilitating fundamental research and clinical applications (231, 232,
597 329, 330). One exciting example of the applicability of these models is the use of patient-derived
598 organoids to predict drug responses for cystic fibrosis treatment (223, 232, 251, 308, 330, 331).
599
600 *Limitations and future directions of 3-D organoids*. As for other models, organoids have
601 limitations that researchers are working to overcome. Variability and quality control challenges

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

602 between experimental preparations includes: 1) heterogeneity in size, shape and viability of
603 organoids within a culture and across different samples; 2) batch-to-batch variability in Matrigel
604 or other ECM, and 3) batch-to-batch variability in growth factor sources. Organoid infection
605 presents challenges as described above. Media cost is high if scaling up due to reliance on
606 specific growth factors. Incorporation of the full array of cell types found *in vivo*, including the
607 diverse collection of immune cells and microbiota has not been attained. Organoid models also
608 lack spontaneous M cell formation (252, 332). Pre-treatment of *in vitro* models with RANKL,
609 exposure to lymphocytes or infection with pathogens like *S*. Typhimurium can induce M cell
610 formation (332-334). Although the mechanism by which M cells spontaneously differentiate in
611 RWV models (11, 153, 172, 176) is unknown, it is possible that the low fluid shear suspension
612 culture environment is important, since flotation of ECM scaffolds was more permissive for
613 differentiation as compared to surface-attached ECM (12, 156, 157). Since organoid models are
614 typically ECM-embedded, another limitation is that the application of the range of biomechanical
615 forces found *in vivo* is limited; however, an iHIO model containing functional neurons that
616 enabled peristalsis-like contractions was reported (257). Combinations of technologies,
617 including organoid-derived 3-D models developed using the RWV bioreactor (203) and organ-
618 on-a-chip (335) are further expanding these capabilities. TEER measurements are also not
619 currently possible with intact organoid models due to their size, structure and because they are
620 ECM-embedded. Some studies have dissociated organoids into 2-D on Transwells to facilitate
621 these measurements, although there can be disadvantages to using this approach, as
622 discussed.
623
624 **Organ-on-a-chip models**. Advanced microfluidic and microfabrication technologies are being
625 broadly applied to develop "organ-on-a-chip" (OAC) models that mimic key aspects of *in vivo*
626 microenvironments. Rather than focusing on recreating the 3-D structure of the entire tissue,
627 this technology aims to recreate a microscale model of the local 3-D architecture and spatial

Accepted Manuscript Posted Online

Infection and Immunity

IAI

628 distribution of dynamic tissue interfaces to mimic tissue- and organ-level functions (336). These
629 devices are designed with micrometer-sized fluidic channels separated by thin, flexible porous
630 membranes that enable development of different tissues in adjacent chambers, while retaining
631 their ability to interact (**Fig. 1B, panel c**) (336-340). These features allow flexibility to model
632 active processes within a tissue, such as vascular-like perfusion. One exciting functional feature
633 engineered into the design of many of these devices is the capability to apply dynamic forces
634 across the tissue to model fluid shear and peristalsis (335, 341-344).
635
636 OAC models vary in complexity, ranging from simple systems containing a single perfused
637 chamber and cell type, to more advanced chips that contain several microchannels,
638 membranes, and assorted cell types, thereby allowing the reconstruction of multiple tissue
639 interfaces (336). Microengineering techniques for these devices have been extensively
640 reviewed (336, 339, 345-350). Chips are commonly made of a silicone polymer called
641 polydimethylsiloxane (PDMS), which is compatible with many cell types and has several
642 advantages, including optical transparency for easy imaging, low cost, flexibility, and high gas
643 permeability (336, 340, 345, 351). PDMS does carry some disadvantages (discussed below), so
644 other options are being explored (351, 352). Depending on experimental requirements, chip
645 design and approaches for tissue development can be altered. Porous membranes can be
646 coated with a variety of matrices/scaffolds (336, 340, 345, 346, 353). Moreover, 3-D bioprinting
647 techniques are facilitating complex spatial patterning of cells and scaffolds (353). Although
648 traditional electrodes used for TEER measurements do not accommodate the small culture area
649 of most OAC models (221), recent studies have integrated custom electrodes (354).
650
651 A variety of OAC platforms have been derived from cell lines, stem cells, and/or primary cells,
652 including small and large intestine (335, 341-343, 354-357), lung (358-362), liver (363-370),
653 kidney (371-373), heart (374-378), cornea (379), skin (380), nervous tissue (381-384), bone

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

654 (385, 386), reproductive tract (387), blood/endothelium and blood-brain barrier (388-394),
655 among others. Once developed, these models typically retain their structural and functional
656 integrity for several weeks (model-specific), further lending to their experimental tractability.
657 Similar to the other 3-D models discussed, OAC models exhibit *in vivo*-like characteristics,
658 including spontaneous differentiation into multiple cell types, polarity/barrier function, formation
659 of local 3-D structures (**Fig. 1B, panel f**), responses to biophysical forces, cytokine production,
660 gene expression, mucus production, responses to nanoparticles and drugs, support of
661 commensals, responses to microbial components (e.g., LPS), and/or susceptibility to microbial
662 infections (335, 336, 340-343, 355-378, 380-395). The application of physical forces across
663 several of these models alters physiological responses, including changes in:
664 expression/localization of tight junctions, barrier integrity/function, polarity and differentiation,
665 cell viability, size, morphology, ECM production, integrin expression, enzyme activity, cytokine
666 responses, chemical/gas exchange gradients, molecular transport, drug responses, bacterial
667 colonization, virion-related cytopathic effects, and/or formation of 3-D structures (e.g., villi) (335,
668 341-344, 346, 359, 360, 362, 372, 373, 377, 378, 385, 388, 389, 396). Importantly, several
669 models have been advanced to incorporate immune cells (343, 360, 397). Below we discuss
670 examples of gut-on-a-chip models that have been applied to study pathogens or commensals.
671
672 *Gut-on-a-chip models.* The Ingber laboratory developed a series of 'mechanically active' gut-on-
673 a-chip models and applied them to study host-microbe interactions (341, 343, 344). They initially
674 constructed a PDMS chip containing two microfluidic channels separated by a flexible, porous
675 ECM-coated membrane (341). Colonic cells were seeded in the upper channel under low fluid
676 shear stress (0.006 - 0.06 dyne/cm^2) and medium also flowed in the bottom chamber. The chip
677 was engineered with dual vacuum chambers on either side of the main microchamber to enable
678 application of a physiological cyclic strain across the membrane to mimic intestinal peristalsis.
679 This led to a highly polarized columnar epithelium and spontaneous formation of 3-D villi-like

Accepted Manuscript Posted Online
Infection and Immunity
IAI
Infection and Immunity
Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

680 folds with basal proliferative cells in the crypt region. Model characterization revealed well-
681 formed tight junctions, mucus production, and multiple intestinal epithelial cell types (absorptive,
682 goblet, enteroendocrine and Paneth cells) (341, 342). The ability of this model to support
683 commensal colonization was assessed using *Lactobacillus rhamnosus* (LGG). Colonization of
684 LGG improved barrier function and was supported for greater than a week without impacting
685 model integrity, consistent with previous *in vivo* observations for probiotics. The model was also
686 applied to study host-virus interactions using CVB (**Fig. 1B, panel i**) (344). Exposure of CVB to
687 the apical surface led to successful viral replication, induction of cytopathic effects (CPE) and
688 polarized (apical) release of pro-inflammatory cytokines. Infection of the basal side led to
689 decreased viral titers and lower CPE, with apical secretion of pro-inflammatory cytokines.
690
691 The above gut-on-a-chip model was further advanced to include immune cells (peripheral blood
692 mononuclear cells/PBMCs) and/or endothelial cells (vascular or lymphatic) (343). This
693 combination of models enabled exploration of the interplay between these factors (and others)
694 in bacterial overgrowth and inflammation in the onset of intestinal injury. Synergistic effects
695 between PBMCs and either non-pathogenic *E. coli*, pathogenic enteroinvasive *E. coli* (EIEC), or
696 purified LPS led to altered barrier function and changes in villus architecture. Similarly, the
697 presence of both PBMCs and LPS led to polarized secretion of basal pro-inflammatory
698 cytokines, which stimulates recruitment of additional immune cells in an *in vivo* scenario.
699 Exposure of the PBMC-containing model to a therapeutic formulation of probiotic bacteria
700 increased barrier function. The formulation reduced EIEC-induced intestinal damage in the
701 model lacking PBMCs, but in the presence of immune cells only delayed injury onset. Cessation
702 of cyclic stretching led to enhanced bacterial overgrowth, even under constant media flow.
703
704 *Limitations and future directions of OAC models*. While there are many advantages to OAC
705 models, there are limitations. Many of these models have multiple cell types which exhibit

Accepted Manuscript Posted Online

706 enhanced 3-D architecture; however, the vast array of native heterogeneous cell types found *in*
707 *vivo* still need to be incorporated and different laboratories are optimizing ECM composition and
708 structure. Along these lines, to our knowledge, no one has yet reported the presence of M cells
709 in gut-on-a-chip models. There is also a strong push for physically linked multi-organ models, or
710 “humans-on-chips” (339, 398). Another limitation is the PDMS material commonly used for chip
711 construction which can absorb small hydrophobic molecules, and interfere with drug screening
712 and cell signaling analysis (339, 351, 352). There are also risks of uncrosslinked PDMS
713 leaching into the culture if the curing process is incomplete, causing cell damage (351, 352).
714 While the small number of cells required can be considered advantageous, in some cases,
715 larger numbers of cells (10^7-10^8) may be required depending on the experiment. Infection
716 studies typically involve many permutations, and it is not uncommon to use several multi-well
717 plates within a single experiment. For example, during colonization assays, samples are
718 harvested at different times and plated for viable bacteria, while others are processed for
719 downstream analyses. Thus, it will be beneficial to incorporate multiple 3-D model systems into
720 infectious disease research depending on the experimental question being addressed, as no
721 single model system is sufficient to address all infectious disease experimental scenarios.
722
723 **Conclusions**
724 Over the past two decades, a multidisciplinary consortia of researchers have been creative in
725 developing 3-D intestinal models of increasing complexity that better mimic the biological,
726 chemical and physical microenvironments of the endogenous tissue for studying host-microbe
727 interactions. These models have been developed using a variety of approaches and are being
728 applied to understand the dynamic relationship between the host, pathogens and commensals
729 that dictate infection outcome and for development of new treatment/prevention strategies.
730 Collectively, these models have ushered in a new era for infectious disease research by offering
731 predictive *in vitro* translational platforms. Indeed, the establishment of 3-D intestinal models and

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

732 their application as human surrogates for infectious disease research have provided specific
733 examples of how the study of microbial pathogenesis can be advanced by using appropriate,
734 biologically meaningful models.
735
736 We are still in the infancy of learning how to build more realistic 3-D tissue models and there
737 remain an endless number of questions and hypotheses to test about how infection actually
738 happens in the body. Continued model advancement to better recapitulate the *in vivo* tissue
739 microenvironment coupled with the application of multiple 3-D model systems will lead to
740 increased translation of research discoveries to practical and significant outcomes. Such
741 advances will be pivotal for the success of personalized medicine approaches using patient-
742 specific normal and diseased cells, and incorporation of the full repertoire of immune cells to
743 predict clinical correlates of protection for vaccine development.
744
745 Toward this goal, we must deeply comprehend 3-D tissue/organ structure and function, the
746 associated microenvironment, and the microorganisms to be studied. It is likewise important that
747 we are aware of and acknowledge the rich history and work of researchers who have long
748 applied 3-D tissue modeling to study host-pathogen interactions. Accordingly, we should revisit
749 past research in the field to help us understand and guide our direction. While it remains a
750 daunting task to gain a complete understanding of infectious disease, the alignment of
751 multidisciplinary research teams dedicated to the establishment of 3-D models that reconstruct
752 the architecture and function of the *in vivo* organ and their application for host-pathogen
753 interaction studies make this an exciting time to be a scientist!
754
755 **Acknowledgements.** We thank Michael Northrop for his illustration in Figure 1. We apologize
756 to authors whose work we were unable to cite due to length limitations given the extensive

Infection and Immunity

Accepted Manuscript Posted Online

757 literature available for each model system. Funded by NASA grants NNX13AM01G and
758 NNX15AL06G (C.A.N., J.B., C.M.O.), and NIH R01-AI081759 (C.B.C, C.A.N.).

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

IAI Infection and Immunity

Accepted Manuscript Posted Online

759 **Figure legend.**

760

761 **Figure 1. Recreating the complex intestinal microenvironment to study host-pathogen**
762 **interactions. (A)** *In vitro* model advancement from 2-D to 3-D by incorporation of physiological
763 factors to better mimic the *in vivo* environment. **(B)** Three-dimensional approaches routinely
764 used to develop advanced intestinal models: (a) RWV bioreactor, (b) organoids, and (c) OAC.
765 (d) Scanning electron micrograph/SEM showing an RWV colon model. (e) Light micrograph of
766 an enteroid model. (f) SEM of a gut-on-a-chip model. (g) Oxygen-dependent host cell co-
767 localization of *S.* Typhimurium in RWV 3-D co-culture model of intestinal epithelium and
768 macrophages. Following aerobic culture of bacteria, no macrophages were found, but following
769 microaerobic culture macrophages were present and either empty (left inset) or contained
770 internalized bacteria (right inset). Macrophages (CD45, yellow), *Salmonella* (green; white when
771 overlaid with CD45), nuclei (DAPI, blue). Scale bar = 10 μm. (h) iHIOs injected with *E. coli*
772 O157:H7. Nuclei (blue), neutrophils (CD11b, red) and *E. coli* (green). Scale bar = 100 μm. (i)
773 CVB-infected gut-on-a-chip. CVB (green), F-actin (red), nuclei (blue). Lumen shown in (A)
774 copyright: nobeastsofierce / 123RF
775 Stock Photo. Panel (b) from (308) (2017) Cell Press; (c) from (345)(2011) Elsevier Ltd.,
776 arrow removed; (d) from (153) under CC Attribution License; (e) from (241) under CC BY 3.0; (f)
777 from (342) (2013) Royal Society of Chemistry. (g) from (172) under CC Attribution 4.0
778 International License. (h) from (261) under CC Attribution License/cropped from original. (i) from
779 (344) under CC Attribution 4.0 International License. Panels c-e, g-i cropped from original.

780

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity IAI Infection and Immunity

Accepted Manuscript Posted Online
Infection and Immunity
IAI
Infection and Immunity

781 **References**
782

783 1. Nickerson C, Ott CM, Wilson JW, Pierson DL. 2004. Microbial responses to microgravity
784 and other low shear environment Microbiology and Molecular Biology Reviews 68:345-
785 361.
786 2. Persat A. 2017. Bacterial mechanotransduction. Curr Opin Microbiol 36:1-6.
787 3. Persat A, Nadell CD, Kim MK, Ingremeau F, Siryaporn A, Drescher K, Wingreen NS,
788 Bassler BL, Gitai Z, Stone HA. 2015. The mechanical world of bacteria. Cell 161:988-97.
789 4. Thomas WE, Trintchina E, Forero M, Vogel V, Sokurenko EV. 2002. Bacterial adhesion
790 to target cells enhanced by shear force. Cell 109:913-23.
791 5. Alsharif G, Ahmad S, Islam MS, Shah R, Busby SJ, Krachler AM. 2015. Host attachment
792 and fluid shear are integrated into a mechanical signal regulating virulence in
793 Escherichia coli O157:H7. Proc Natl Acad Sci U S A 112:5503-8.
794 6. Fang FC, Frawley ER, Tapscott T, Vazquez-Torres A. 2016. Bacterial Stress Responses
795 during Host Infection. Cell Host Microbe 20:133-43.
796 7. McGuckin MA, Linden SK, Sutton P, Florin TH. 2011. Mucin dynamics and enteric
797 pathogens. Nat Rev Microbiol 9:265-78.
798 8. Barrila J, Radtke AL, Crabbe A, Sarker SF, Herbst-Kralovetz MM, Ott CM, Nickerson
799 CA. 2010. Organotypic 3D cell culture models: using the rotating wall vessel to study
800 host-pathogen interactions. Nat Rev Microbiol 8:791-801.
801 9. Ibarra JA, Steele-Mortimer O. 2009. Salmonella--the ultimate insider. Salmonella
802 virulence factors that modulate intracellular survival. Cell Microbiol 11:1579-86.
803 10. Costello CM, Sorna RM, Goh YL, Cengic I, Jain NK, March JC. 2014. 3-D intestinal
804 scaffolds for evaluating the therapeutic potential of probiotics. Mol Pharm 11:2030-9.
805 11. Nickerson CA, Goodwin TJ, Terlonge J, Ott CM, Buchanan KL, Uicker WC, Emami K,
806 LeBlanc CL, Ramamurthy R, Clarke MS, Vanderburg CR, Hammond T, Pierson DL.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

807 2001. Three-dimensional tissue assemblies: novel models for the study of Salmonella
808 enterica serovar Typhimurium pathogenesis. Infect Immun 69:7106-20.
809 12. Simian M, Bissell MJ. 2017. Organoids: A historical perspective of thinking in three
810 dimensions. J Cell Biol 216:31-40.
811 13. Bissell MJ. 1981. The Differentiated State of Normal and Malignant Cells or How to
812 Define a "Normal" Cell in Culture. International Review of Cytology 70:27-100.
813 14. Schwarz RI, Bissell MJ. 1977. Dependence of the differentiated state on the cellular
814 environment: modulation of collagen synthesis in tendon cells. Proceedings of the
815 National Academy of Sciences of the United States of America 74:4453-4457.
816 15. Griffith LG, Swartz MA. 2006. Capturing complex 3D tissue physiology in vitro. Nat Rev
817 Mol Cell Biol 7:211-24.
818 16. Yamada KM, Cukierman E. 2007. Modeling tissue morphogenesis and cancer in 3D.
819 Cell 130:601-10.
820 17. Bissell MJ, Aggeler J. 1987. Dynamic reciprocity: how do extracellular matrix and
821 hormones direct gene expression? Prog Clin Biol Res 249:251-62.
822 18. Jorgens DM, Inman JL, Wojcik M, Robertson C, Palsdottir H, Tsai WT, Huang H, Bruni-
823 Cardoso A, Lopez CS, Bissell MJ, Xu K, Auer M. 2017. Deep nuclear invaginations are
824 linked to cytoskeletal filaments - integrated bioimaging of epithelial cells in 3D culture. J
825 Cell Sci 130:177-189.
826 19. Maniotis AJ, Chen CS, Ingber DE. 1997. Demonstration of mechanical connections
827 between integrins, cytoskeletal filaments, and nucleoplasm that stabilize
828 nuclear structure. Proceedings of the National Academy of Sciences 94:849-854.
829 20. Bissell MJ, Hall HG, Parry G. 1982. How does the extracellular matrix direct gene
830 expression? Journal of Theoretical Biology 99:31-68.
831 21. Boudreau N, Myers C, Bissell MJ. 1995. From laminin to lamin: regulation of tissue-
832 specific gene expression by the ECM. Trends Cell Biol 5:1-4.

Infection and Immunity
IAI
Infection and Immunity
Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

Infection and Immunity

IAI

833 22. Tapley EC, Starr DA. 2013. Connecting the nucleus to the cytoskeleton by SUN-KASH
834 bridges across the nuclear envelope. Curr Opin Cell Biol 25:57-62.
835 23. Xu R, Spencer VA, Groesser DL, Bissell MJ. 2010. Laminin regulates PI3K basal
836 localization and activation to sustain STAT5 activation. Cell Cycle 9:4315-22.
837 24. Kim DH, Wirtz D. 2015. Cytoskeletal tension induces the polarized architecture of the
838 nucleus. Biomaterials 48:161-72.
839 25. Hagios C, Lochter A, Bissell MJ. 1998. Tissue architecture: the ultimate regulator of
840 epithelial function? Philos Trans R Soc Lond B Biol Sci 353:857-70.
841 26. Doyle AD, Yamada KM. 2016. Mechanosensing via cell-matrix adhesions in 3D
842 microenvironments. Exp Cell Res 343:60-6.
843 27. Ingber DE. 2003. Tensegrity I. Cell structure and hierarchical systems biology. J Cell Sci
844 116:1157-73.
845 28. Ingber DE. 2003. Mechanobiology and diseases of mechanotransduction. Ann Med
846 35:564-77.
847 29. Ingber DE. 2003. Tensegrity II. How structural networks influence cellular information
848 processing networks. Journal of Cell Science 116:1397-1408.
849 30. Ingber DE. 2008. Tensegrity-based mechanosensing from macro to micro. Prog Biophys
850 Mol Biol 97:163-79.
851 31. Ingber DE. 2006. Cellular mechanotransduction: putting all the pieces together again.
852 FASEB J 20:811-27.
853 32. Gruenheid S, Finlay BB. 2003. Microbial pathogenesis and cytoskeletal function. Nature
854 422:775-81.
855 33. Taylor MP, Koyuncu OO, Enquist LW. 2011. Subversion of the actin cytoskeleton during
856 viral infection. Nat Rev Microbiol 9:427-39.
857 34. Delorme-Axford E, Coyne CB. 2011. The Actin Cytoskeleton as a Barrier to Virus
858 Infection of Polarized Epithelial Cells. Viruses 3:2462.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity

Accepted Manuscript Posted Online

859 35. Nickerson CA, Ott CM, Mister SJ, Morrow BJ, Burns-Keliher L, Pierson DL. 2000.
860 Microgravity as a Novel Environmental Signal Affecting Salmonella enterica Serovar
861 Typhimurium Virulence. Infection and Immunity 68:3147-3152.
862 36. Wilson JW, Ott CM, Ramamurthy R, Porwollik S, McClelland M, Pierson DL, Nickerson
863 CA. 2002. Low-Shear modeled microgravity alters the *Salmonella enterica* serovar
864 typhimurium stress response in an RpoS-independent manner. Appl Environ Microbiol
865 68:5408-16.
866 37. Wilson JW, Ramamurthy R, Porwollik S, McClelland M, Hammond T, Allen P, Ott CM,
867 Pierson DL, Nickerson CA. 2002. Microarray analysis identifies *Salmonella* genes
868 belonging to the low-shear modeled microgravity regulon. Proc Natl Acad Sci U S A
869 99:13807-13812.
870 38. Nauman EA, Ott CM, Sander E, Tucker DL, Pierson D, Wilson JW, Nickerson CA. 2007.
871 Novel quantitative biosystem for modeling physiological fluid shear stress on cells. Appl
872 Environ Microbiol 73:699-705.
873 39. Crabbé A, De Boever P, Van Houdt R, Moors H, Mergeay M, Cornelis P. 2008. Use of
874 the rotating wall vessel technology to study the effect of shear stress on growth
875 behaviour of *Pseudomonas aeruginosa* PA01. Environ Microbiol 10:2098-110.
876 40. Crabbé A, Pycke B, Van Houdt R, Monsieurs P, Nickerson C, Leys N, Cornelis P. 2010.
877 Response of *Pseudomonas aeruginosa* PAO1 to low shear modelled microgravity
878 involves AlgU regulation. Environ Microbiol 12:1545-1564.
879 41. Pacello F, Rotilio G, Battistoni A. 2012. Low-Shear Modeled Microgravity Enhances
880 Salmonella Enterica Resistance to Hydrogen Peroxide Through a Mechanism Involving
881 KatG and KatN. Open Microbiol J 6:53-64.
882 42. Aprikian P, Interlandi G, Kidd BA, Le Trong I, Tchesnokova V, Yakovenko O, Whitfield
883 MJ, Bullitt E, Stenkamp RE, Thomas WE, Sokurenko EV. 2011. The bacterial fimbrial tip
884 acts as a mechanical force sensor. PLoS Biol 9:e1000617.

Infection and Immunity
IAI
Infection and Immunity
Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

885 43. Isberg RR, Barnes P. 2002. Dancing with the host; flow-dependent bacterial adhesion.
886 Cell 110:1-4.
887 44. Persat A, Inclan YF, Engel JN, Stone HA, Gitai Z. 2015. Type IV pili mechanochemically
888 regulate virulence factors in Pseudomonas aeruginosa. Proc Natl Acad Sci U S A
889 112:7563-8.
890 45. Yang J, Barrila J, Roland KL, Ott CM, Nickerson CA. 2016. Physiological fluid shear
891 alters the virulence potential of invasive multidrug-resistant non-typhoidal Salmonella
892 Typhimurium D23580. NPJ Microgravity 2:16021.
893 46. Dingemans J, Monsieurs P, Yu SH, Crabbe A, Forstner KU, Malfroot A, Cornelis P, Van
894 Houdt R. 2016. Effect of Shear Stress on Pseudomonas aeruginosa Isolated from the
895 Cystic Fibrosis Lung. MBio 7.
896 47. Castro SL, Nelman-Gonzalez M, Nickerson CA, Ott CM. 2011. Induction of attachment-
897 independent biofilm formation and repression of Hfq expression by low-fluid-shear
898 culture of Staphylococcus aureus. Appl Environ Microbiol 77:6368-78.
899 48. Tarbell JM, Weinbaum S, Kamm RD. 2005. Cellular fluid mechanics and
900 mechanotransduction. Ann Biomed Eng 33:1719-23.
901 49. Kaul H, Ventikos Y. 2015. Dynamic reciprocity revisited. J Theor Biol 370:205-8.
902 50. Rutkowski JM, Swartz MA. 2007. A driving force for change: interstitial flow as a
903 morphoregulator. Trends in Cell Biology 17:44-50.
904 51. Long JP, S. Pierson S, Hughes JH. 1998. Rhinovirus replication in HeLa cells cultured
905 under conditions of simulated microgravity. Aviation, Space, and Environ Med 69:851-
906 856.
907 52. Bissell MJ, Rizki A, Mian IS. 2003. Tissue architecture: the ultimate regulator of breast
908 epithelial function. Curr Opin Cell Biol 15:753-62.
909 53. Correia AL, Bissell MJ. 2012. The tumor microenvironment is a dominant force in
910 multidrug resistance. Drug Resist Updat 15:39-49.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity IAI Infection and Immunity

Accepted Manuscript Posted Online

Infection and Immunity

IAI

911 54. Nelson CM, Bissell MJ. 2006. Of extracellular matrix, scaffolds, and signaling: tissue
912 architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol
913 22:287-309.
914 55. Schmeichel KL, Bissell MJ. 2003. Modeling tissue-specific signaling and organ function
915 in three dimensions. J Cell Sci 116:2377-88.
916 56. Bals R, Hiemstra PS. 2004. Innate immunity in the lung: how epithelial cells fight against
917 respiratory pathogens. European Respiratory Journal 23:327-333.
918 57. Crabbé A, Ledesma MA, Nickerson CA. 2014. Mimicking the host and its
919 microenvironment in vitro for studying mucosal infections by *Pseudomonas aeruginosa*.
920 Pathog Dis 71:1-19.
921 58. Duerkop BA, Vaishnava S, Hooper LV. 2009. Immune Responses to the Microbiota at
922 the Intestinal Mucosal Surface. Immunity 31:368-376.
923 59. Kraehenbuhl JP, Corbet M. 2004. Keeping the gut microflora at bay. Science 303:1624-
924 1625.
925 60. Lopetuso LR, Scaldaferri F, Franceschi F, Gasbarrini A. 2014. The gastrointestinal
926 microbiome - functional interference between stomach and intestine. Best Pract Res Clin
927 Gastroenterol 28:995-1002.
928 61. Singh B, Fleury C, Jalalvand F, Riesbeck K. 2012. Human pathogens utilize host
929 extracellular matrix proteins laminin and collagen for adhesion and invasion of the host.
930 FEMS Microbiol Rev 36:1122-80.
931 62. Allen CA, Niesel DW, Torres AG. 2008. The effects of low-shear stress on Adherent-
932 invasive *Escherichia coli*. Environ Microbiol 10:1512-25.
933 63. Fonseca AP, Sousa JC. 2007. Effect of shear stress on growth, adhesion and biofilm
934 formation of *Pseudomonas aeruginosa* with antibiotic-induced morphological changes.
935 Int J Antimicrob Agents 30:236-41.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity

Accepted Manuscript Posted Online

936 64. Lynch SV, Mukundakrishnan K, Benoit MR, Ayyaswamy PS, Matin A. 2006. *Escherichia*
937 *coli* biofilms formed under low-shear modeled microgravity in a ground-based system.
938 Appl Environ Microbiol 72:7701-10.
939 65. Mestecky J, Strober W, Russell MW, Kelsall BL, Cheroutre H, Lambrecht BN. 2015.
940 Mucosal Immunology. Elsevier, United States of America.
941 66. Gerbe F, Legraverend C, Jay P. 2012. The intestinal epithelium tuft cells: specification
942 and function. Cell Mol Life Sci 69:2907-17.
943 67. Peterson LW, Artis D. 2014. Intestinal epithelial cells: regulators of barrier function and
944 immune homeostasis. Nat Rev Immunol 14:141-53.
945 68. Mowat AM, Agace WW. 2014. Regional specialization within the intestinal immune
946 system. Nat Rev Immunol 14:667-685.
947 69. Cerutti A. 2008. The regulation of IgA class switching. Nat Rev Immunol 8:421-34.
948 70. Cerutti A, Rescigno M. 2008. The biology of intestinal immunoglobulin A responses.
949 Immunity 28:740-50.
950 71. Holmgren J, Czerkinsky C. 2005. Mucosal immunity and vaccines. Nat Med 11:S45-53.
951 72. Kraehenbuhl JP, Corbett M. 2004. Immunology. Keeping the gut microflora at bay.
952 Science 303:1624-5.
953 73. Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. 2008. The immune geography
954 of IgA induction and function. Mucosal Immunol 1:11-22.
955 74. Engel J, Eran Y. 2011. Subversion of mucosal barrier polarity by *Pseudomonas*
956 *aeruginosa*. Front Microbiol 2:114.
957 75. Zihni C, Balda MS, Matter K. 2014. Signalling at tight junctions during epithelial
958 differentiation and microbial pathogenesis. J Cell Sci 127:3401-13.
959 76. Schneeberger K, Roth S, Nieuwenhuis EES, Middendorp S. 2018. Intestinal epithelial
960 cell polarity defects in disease: lessons from microvillus inclusion disease. Dis Model
961 Mech 11.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

962 77. Jung C, Hugot JP, Barreau F. 2010. Peyer's Patches: The Immune Sensors of the
963 Intestine. Int J Inflam 2010:823710.
964 78. Cohen CJ, Shieh JTC, Pickles RJ, Okegawa T, Hsieh J-T, Bergelson JM. 2001. The
965 coxsackievirus and adenovirus receptor is a transmembrane component of the tight
966 junction. Proceedings of the National Academy of Sciences 98:15191-15196.
967 79. Barton ES, Forrest JC, Connolly JL, Chappell JD, Liu Y, Schnell FJ, Nusrat A, Parkos
968 CA, Dermody TS. Junction Adhesion Molecule Is a Receptor for Reovirus. Cell 104:441-
969 451.
970 80. Bonazzi M, Cossart P. 2011. Impenetrable barriers or entry portals? The role of cell-cell
971 adhesion during infection. J Cell Biol 195:349-58.
972 81. Höner zu Bentrup K, Ramamurthy R, Ott CM, Emami K, Nelman-Gonzalez M, Wilson
973 JW, Richter EG, Goodwin TJ, Alexander JS, Pierson DL, Pellis N, Buchanan KL,
974 Nickerson CA. 2006. Three-dimensional organotypic models of human colonic
975 epithelium to study the early stages of enteric salmonellosis. Microbes and Infection
976 8:1813-1825.
977 82. Fleiszig SM, Evans DJ, Do N, Vallas V, Shin S, Mostov KE. 1997. Epithelial cell polarity
978 affects susceptibility to Pseudomonas aeruginosa invasion and cytotoxicity. Infection and
979 Immunity 65:2861-2867.
980 83. Hurley BP, McCormick BA. 2003. Translating tissue culture results into animal models:
981 the case of Salmonella typhimurium. Trends in Microbiology 11:562-569.
982 84. Law RJ, Gur-Arie L, Rosenshine I, Finlay BB. 2013. In Vitro and In Vivo Model Systems
983 for Studying Enteropathogenic Escherichia coli Infections. Cold Spring Harbor
984 Perspectives in Medicine 3.
985 85. Ashida H, Ogawa M, Kim M, Mimuro H, Sasakawa C. 2012. Bacteria and host
986 interactions in the gut epithelial barrier. Nat Chem Biol 8:36-45.

Infection and Immunity
IAI
Infection and Immunity
Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online
Infection and Immunity
IAI
Infection and Immunity

987 86. Clemente JC, Ursell LK, Parfrey LW, Knight R. 2012. The impact of the gut microbiota
988 on human health: an integrative view. Cell 148:1258-70.
989 87. Krishnan S, Alden N, Lee K. 2015. Pathways and functions of gut microbiota metabolism
990 impacting host physiology. Curr Opin Biotechnol 36:137-145.
991 88. Chu H, Mazmanian SK. 2013. Innate immune recognition of the microbiota promotes
992 host-microbial symbiosis. Nat Immunol 14:668-75.
993 89. Vaishnava S, Yamamoto M, Severson KM, Ruhn KA, Yu X, Koren O, Ley R, Wakeland
994 EK, Hooper LV. 2011. The antibacterial lectin RegIIIgamma promotes the spatial
995 segregation of microbiota and host in the intestine. Science 334:255-8.
996 90. Maynard CL, Elson CO, Hatton RD, Weaver CT. 2012. Reciprocal interactions of the
997 intestinal microbiota and immune system. Nature 489:231-41.
998 91. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson
999 KE, Relman DA. 2005. Diversity of the human intestinal microbial flora. Science
1000 308:1635-1638.
1001 92. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. 2012. Diversity, stability
1002 and resilience of the human gut microbiota. Nature 489:220-30.
1003 93. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. 2007. The
1004 human microbiome project. Nature 449:804-10.
1005 94. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N,
1006 Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng
1007 H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A,
1008 Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian
1009 M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F,
1010 Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, et al. 2010. A human gut
1011 microbial gene catalogue established by metagenomic sequencing. Nature 464:59-65.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

1012 95. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR,
1013 Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L,
1014 Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F,
1015 Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims
1016 S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM,
1017 Brunak S, Dore J, Meta HITC, Antolin M, Artiguenave F, Blottiere HM, Almeida M,
1018 Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, et al. 2011.
1019 Enterotypes of the human gut microbiome. Nature 473:174-80.
1020 96. Donaldson GP, Lee SM, Mazmanian SK. 2015. Gut biogeography of the bacterial
1021 microbiota. Nat Rev Microbiol doi:10.1038/nrmicro3552.
1022 97. Lavelle A, Lennon G, O'Sullivan O, Docherty N, Balfe A, Maguire A, Mulcahy HE,
1023 Doherty G, O'Donoghue D, Hyland J, Ross RP, Coffey JC, Sheahan K, Cotter PD,
1024 Shanahan F, Winter DC, O'Connell PR. 2015. Spatial variation of the colonic microbiota
1025 in patients with ulcerative colitis and control volunteers. Gut 64:1553-61.
1026 98. Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN,
1027 Kinross J, Smidt H, Tuohy KM, Thomas LV, Zoetendal EG, Hart A. 2015. The gut
1028 microbiota and host health: a new clinical frontier. Gut doi:10.1136/gutjnl-2015-309990.
1029 99. Lynch SV, Pedersen O. 2016. The Human Intestinal Microbiome in Health and Disease.
1030 N Engl J Med 375:2369-2379.
1031 100. Kassam Z, Lee CH, Yuan Y, Hunt RH. 2013. Fecal microbiota transplantation for
1032 Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol
1033 108:500-8.
1034 101. Gianotti RJ, Moss AC. 2017. Fecal Microbiota Transplantation: From Clostridium difficile
1035 to Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) 13:209-213.
1036 102. Parker D, Prince A. 2011. Innate immunity in the respiratory epithelium. Am J Respir Cell
1037 Mol Biol 45:189-201.

Infection and Immunity IAI Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

1038 103. Johansson ME, Ambort D, Pelaseyed T, Schutte A, Gustafsson JK, Ermund A,
1039 Subramani DB, Holmen-Larsson JM, Thomsson KA, Bergstrom JH, van der Post S,
1040 Rodriguez-Pineiro AM, Sjovall H, Backstrom M, Hansson GC. 2011. Composition and
1041 functional role of the mucus layers in the intestine. Cell Mol Life Sci 68:3635-41.
1042 104. Johansson ME, Larsson JM, Hansson GC. 2011. The two mucus layers of colon are
1043 organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial
1044 interactions. Proc Natl Acad Sci U S A 108 Suppl 1:4659-65.
1045 105. Li H, Limenitakis JP, Fuhrer T, Geuking MB, Lawson MA, Wyss M, Brugiroux S, Keller I,
1046 Macpherson JA, Rupp S, Stolp B, Stein JV, Stecher B, Sauer U, McCoy KD,
1047 Macpherson AJ. 2015. The outer mucus layer hosts a distinct intestinal microbial niche.
1048 Nat Commun 6:8292.
1049 106. Rogier EW, Frantz AL, Bruno MEC, Kaetzel CS. 2014. Secretory IgA is Concentrated in
1050 the Outer Layer of Colonic Mucus along with Gut Bacteria. Pathogens 3:390-403.
1051 107. Frantz C, Stewart KM, Weaver VM. 2010. The extracellular matrix at a glance. Journal of
1052 Cell Science 123:4195-4200.
1053 108. Bonnans C, Chou J, Werb Z. 2014. Remodelling the extracellular matrix in development
1054 and disease. Nat Rev Mol Cell Biol 15:786-801.
1055 109. Ray SJ, Franki SN, Pierce RH, Dimitrova S, Koteliansky V, Sprague AG, Doherty PC, de
1056 Fougerolles AR, Topham DJ. 2004. The collagen binding alpha1beta1 integrin VLA-1
1057 regulates CD8 T cell-mediated immune protection against heterologous influenza
1058 infection. Immunity 20:167-79.
1059 110. Mammoto T, Mammoto A, Ingber DE. 2013. Mechanobiology and developmental control.
1060 Annu Rev Cell Dev Biol 29:27-61.
1061 111. Button B, Boucher RC, University of North Carolina Virtual Lung G. 2008. Role of
1062 mechanical stress in regulating airway surface hydration and mucus clearance rates.
1063 Respir Physiol Neurobiol 163:189-201.

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

1064 112. Gayer CP, Basson MD. 2009. The effects of mechanical forces on intestinal physiology
1065 and pathology. Cell Signal 21:1237-44.
1066 113. Scott SM, Knowles CH, Wang D, Yazaki E, Picon L, Wingate DL, Lindberg G. 2006. The
1067 nocturnal jejunal migrating motor complex: defining normal ranges by study of 51 healthy
1068 adult volunteers and meta-analysis. Neurogastroenterol Motil 18:927-35.
1069 114. Otterson MF, Sarr MG. 1993. Normal physiology of small intestinal motility. Surg Clin
1070 North Am 73:1173-92.
1071 115. Guo P, Weinstein AM, Weinbaum S. 2000. A hydrodynamic mechanosensory
1072 hypothesis for brush border microvilli. Am J Physiol Renal Physiol 279:F698-712.
1073 116. Ashida N, Takechi H, Kita T, Arai H. 2003. Vortex-mediated mechanical stress induces
1074 integrin-dependent cell adhesion mediated by inositol 1,4,5-trisphosphate-sensitive
1075 Ca2+ release in THP-1 cells. J Biol Chem 278:9327-31.
1076 117. Kim M, Javed NH, Yu JG, Christofi F, Cooke HJ. 2001. Mechanical stimulation activates
1077 Galphaq signaling pathways and 5-hydroxytryptamine release from human carcinoid
1078 BON cells. J Clin Invest 108:1051-9.
1079 118. Roskelley CD, Bissell MJ. 1995. Dynamic reciprocity revisited: a continuous,
1080 bidirectional flow of information between cells and the extracellular matrix regulates
1081 mammary epithelial cell function. Biochem Cell Biol 73:391-7.
1082 119. Zhang J, Owen CR, Sanders MA, Turner JR, Basson MD. 2006. The motogenic effects
1083 of cyclic mechanical strain on intestinal epithelial monolayer wound closure are matrix
1084 dependent. Gastroenterology 131:1179-89.
1085 120. Zhang S, Kingsley RA, Santos RL, Andrews-Polymenis H, Raffatellu M, Figueiredo J,
1086 Nunes J, Tsolis RM, Adams LG, Baumler AJ. 2003. Molecular pathogenesis of
1087 Salmonella enterica serotype typhimurium-induced diarrhea. Infect Immun 71:1-12.
1088 121. Lu P, Takai K, Weaver VM, Werb Z. 2011. Extracellular matrix degradation and
1089 remodeling in development and disease. Cold Spring Harb Perspect Biol 3.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity
IAI
Infection and Immunity

Accepted Manuscript Posted Online

1090 122. Abbott A. 2003. Cell culture: biology's new dimension. Nature 424:870-2.

1091 123. de Bentzmann S, Plotkowski C, Puchelle E. 1996. Receptors in the
1092 *Pseudomonas aeruginosa* adherence to injured and repairing airway epithelium.
1093 Am J Respir Crit Care Med 154:S155-62.

1094 124. de Bentzmann S, Roger P, Dupuit F, Bajolet-Laudinat O, Fuchey C, Plotkowski MC,
1095 Puchelle E. 1996. Asialo GM1 is a receptor for *Pseudomonas aeruginosa* adherence to
1096 regenerating respiratory epithelial cells. Infect Immun 64:1582-8.

1097 125. Ljungh A, Moran AP, Wadstrom T. 1996. Interactions of bacterial adhesins with
1098 extracellular matrix and plasma proteins: pathogenic implications and therapeutic
1099 possibilities. FEMS Immunol Med Microbiol 16:117-26.

1100 126. Ljungh A, Wadstrom T. 1996. Interactions of bacterial adhesins with the extracellular
1101 matrix. Adv Exp Med Biol 408:129-40.

1102 127. Plotkowski MC, Tournier JM, Puchelle E. 1996. *Pseudomonas aeruginosa* strains
1103 possess specific adhesins for laminin. Infect Immun 64:600-5.

1104 128. Wolf DA, Schwarz RP. 1991. Analysis of gravity-induced particle motion and fluid
1105 perfusion flow in the NASA-designed rotating zero-head space tissue culture vessel.,

1106 129. Basson MD. 2003. Paradigms for mechanical signal transduction in the intestinal
1107 epithelium. Category: molecular, cell, and developmental biology. Digestion 68:217-25.

1108 130. Beeson JG, Rogerson SJ, Cooke BM, Reeder JC, Chai W, Lawson AM, Molyneux ME,
1109 Brown GV. 2000. Adhesion of Plasmodium falciparum-infected erythrocytes to
1110 hyaluronic acid in placental malaria. Nat Med 6:86-90.

1111 131. Cai Z, Xin J, Pollock DM, Pollock JS. 2000. Shear stress-mediated NO production in
1112 inner medullary collecting duct cells. American Journal of Physiology - Renal Physiology
1113 279:F270-F274.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

1114 132. Creasy RK, Reznik R. 1984. Maternal-Fetal Medicine: Principles and Practice. WB
1115 Saunders Company, Philadelphia.
1116 133. Stock UA, Vacanti JP. 2001. Cardiovascular physiology during fetal development and
1117 implications for tissue engineering. Tissue Eng 7:1-7.
1118 134. Vetsch JR, Betts DC, Muller R, Hofmann S. 2017. Flow velocity-driven differentiation of
1119 human mesenchymal stromal cells in silk fibroin scaffolds: A combined experimental and
1120 computational approach. PLoS One 12:e0180781.
1121 135. Liu YS, Lee OK. 2014. In search of the pivot point of mechanotransduction:
1122 mechanosensing of stem cells. Cell Transplant 23:1-11.
1123 136. Geuss LR, Suggs LJ. 2013. Making cardiomyocytes: How mechanical stimulation can
1124 influence differentiation of pluripotent stem cells. Biotechnology Progress 29:1089-1096.
1125 137. Chen G, Lv Y, Guo P, Lin C, Zhang X, Yang L, Xu Z. 2013. Matrix mechanics and fluid
1126 shear stress control stem cells fate in three dimensional microenvironment. Curr Stem
1127 Cell Res Ther 8:313-23.
1128 138. Adamo L, Garcia-Cardena G. 2011. Directed stem cell differentiation by fluid mechanical
1129 forces. Antioxid Redox Signal 15:1463-73.
1130 139. Ando J, Yamamoto K. 2009. Vascular mechanobiology: endothelial cell responses to
1131 fluid shear stress. Circ J 73:1983-92.
1132 140. Patwari P, Lee RT. 2008. Mechanical control of tissue morphogenesis. Circ Res
1133 103:234-43.
1134 141. Miura S, Sato K, Kato-Negishi M, Teshima T, Takeuchi S. 2015. Fluid shear triggers
1135 microvilli formation via mechanosensitive activation of TRPV6. Nat Commun 6:8871.
1136 142. Jessup JM, Frantz M, Sonmez-Alpan E, Locker J, Skena K, Waller H, Battle P,
1137 Nachman A, Weber ME, Thomas DA, Curbeam RL, Jr., Baker TL, Goodwin TJ. 2000.
1138 Microgravity Culture Reduces Apoptosis and Increases the Differentiation of a Human

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity
IAI
Infection and Immunity

Accepted Manuscript Posted Online

1139 Colorectal Carcinoma Cell Line. In Vitro Cellular & Developmental Biology Animal
1140 36:367-373.
1141 143. Zhau HE, Goodwin TJ, Chang SM, Baker TL, Chung LW. 1997. Establishment of a
1142 three-dimensional human prostate organoid coculture under microgravity-simulated
1143 conditions: evaluation of androgen-induced growth and PSA expression. In Vitro Cell
1144 Dev Biol Anim 33:375-80.
1145 144. Alcantara Warren C, Destura RV, Sevilleja JE, Barroso LF, Carvalho H, Barrett LJ,
1146 O'Brien AD, Guerrant RL. 2008. Detection of epithelial-cell injury, and quantification of
1147 infection, in the HCT-8 organoid model of cryptosporidiosis. J Infect Dis 198:143-9.
1148 145. Carterson AJ, Honer zu Bentrup K, Ott CM, Clarke MS, Pierson DL, Vanderburg CR,
1149 Buchanan KL, Nickerson CA, Schurr MJ. 2005. A549 lung epithelial cells grown as
1150 three-dimensional aggregates: alternative tissue culture model for *Pseudomonas*
1151 *aeruginosa* pathogenesis. Infect Immun 73:1129-40.
1152 146. Carvalho HM, Teel LD, Goping G, O'Brien AD. 2005. A three-dimensional tissue culture
1153 model for the study of attach and efface lesion formation by enteropathogenic and
1154 enterohaemorrhagic Escherichia coli. Cell Microbiol 7:1771-81.
1155 147. Drummond CG, Nickerson CA, Coyne CB. 2016. A Three-Dimensional Cell Culture
1156 Model To Study Enterovirus Infection of Polarized Intestinal Epithelial Cells. mSphere 1.
1157 148. David J, Sayer NM, Sarkar-Tyson M. 2014. The use of a three-dimensional cell culture
1158 model to investigate host-pathogen interactions of *Francisella tularensis* in human lung
1159 epithelial cells. Microbes Infect 16:735-45.
1160 149. Chang TT, Hughes-Fulford M. 2014. Molecular mechanisms underlying the enhanced
1161 functions of three-dimensional hepatocyte aggregates. Biomaterials 35:2162-71.
1162 150. Hjelm BE, Berta AN, Nickerson CA, Arntzen CJ, Herbst-Kralovetz MM. 2010.
1163 Development and characterization of a three-dimensional organotypic human vaginal
1164 epithelial cell model. Biol Reprod 82:617-27.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity IAI Infection and Immunity

Accepted Manuscript Posted Online

Infection and Immunity

IAI

1165 151. Lamarca HL, Ott CM, Honer Zu Bentrup K, Leblanc CL, Pierson DL, Nelson AB,
1166 Scandurro AB, Whitley GS, Nickerson CA, Morris CA. 2005. Three-dimensional growth
1167 of extravillous cytotrophoblasts promotes differentiation and invasion. Placenta 26:709-
1168 20.
1169 152. McConkey CA, Delorme-Axford E, Nickerson CA, Kim KS, Sadovsky Y, Boyle JP, Coyne
1170 CB. 2016. A three-dimensional culture system recapitulates placental
1171 syncytiotrophoblast development and microbial resistance. Sci Adv 2:e1501462.
1172 153. Radtke AL, Wilson JW, Sarker S, Nickerson CA. 2010. Analysis of interactions of
1173 Salmonella type three secretion mutants with 3-D intestinal epithelial cells. PLoS One
1174 5:e15750.
1175 154. Sainz B, Jr., TenCate V, Uprichard SL. 2009. Three-dimensional Huh7 cell culture
1176 system for the study of Hepatitis C virus infection. Virol J 6:103.
1177 155. Duray PH, Hatfill SJ, Pellis NR. 1997. Tissue culture in microgravity. Science & medicine
1178 4:46-55.
1179 156. Michalopoulos G, Pitot HC. 1975. Primary culture of parenchymal liver cells on collagen
1180 membranes. Morphological and biochemical observations. Exp Cell Res 94:70-8.
1181 157. Emerman JT, Pitelka DR. 1977. Maintenance and induction of morphological
1182 differentiation in dissociated mammary epithelium on floating collagen membranes. In
1183 Vitro 13:316-28.
1184 158. Nickerson CA, Ott CM, Wilson JW, Ramamurthy R, LeBlanc CL, Honer zu Bentrup K,
1185 Hammond T, Pierson DL. 2003. Low-shear modeled microgravity: a global
1186 environmental regulatory signal affecting bacterial gene expression, physiology, and
1187 pathogenesis. J Microbiol Methods 54:1-11.
1188 159. Soni A, O'Sullivan L, Quick LN, Ott CM, Nickerson CA, Wilson JW. 2014. Conservation
1189 of the Low-shear Modeled Microgravity Response in Enterobacteriaceae and Analysis of
1190 the trp Genes in this Response. Open Microbiol J 8:51-8.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity

Accepted Manuscript Posted Online

1191 160. Grant KC, Khodadad CLM, Foster JS. 2013. Role of Hfq in an animal–microbe
1192 symbiosis under simulated microgravity conditions. International Journal of Astrobiology
1193 13:53-61.
1194 161. Altenburg SD, Nielsen-Preiss SM, Hyman LE. 2008. Increased filamentous growth of
1195 Candida albicans in simulated microgravity. Genomics Proteomics Bioinformatics 6:42-
1196 50.
1197 162. Baker PW, Meyer ML, Leff LG. 2004. Escherichia coli growth under modeled reduced
1198 gravity. Microgravity Sci Technol 15:39-44.
1199 163. Demain AL, Fang A. 2001. Secondary metabolism in simulated microgravity. Chem Rec
1200 1:333-346.
1201 164. Fang A, Pierson DL, Koenig DW, Mishra SK, Demain AL. 1997. Effect of simulated
1202 microgravity and shear stress on microcin B17 production by Escherichia coli and on its
1203 excretion into the medium. Appl Environ Microbiol 63:4090-2.
1204 165. Lynch SV, Brodie EL, Matin A. 2004. Role and regulation of sigma S in general
1205 resistance conferred by low-shear simulated microgravity in Escherichia coli. J Bacteriol
1206 186:8207-12.
1207 166. Tucker DL, Ott CM, Huff S, Fofanov Y, Pierson DL, Willson RC, Fox GE. 2007.
1208 Characterization of Escherichia coli MG1655 grown in a low-shear modeled microgravity
1209 environment. BMC Microbiol 7:15.
1210 167. Abshire CF, Prasai K, Soto I, Shi R, Concha M, Baddoo M, Flemington EK, Ennis DG,
1211 Scott RS, Harrison L. 2016. Exposure of Mycobacterium marinum to low-shear modeled
1212 microgravity: effect on growth, the transcriptome and survival under stress. NPJ
1213 Microgravity 2:16038.
1214 168. Orsini SS, Lewis AM, Rice KC. 2017. Investigation of simulated microgravity effects on
1215 Streptococcus mutans physiology and global gene expression. NPJ Microgravity 3:4.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity

IAI

Infection and Immunity

Accepted Manuscript Posted Online

Infection and Immunity

IAI

1216 169. Goodwin TJ, Schroeder WF, Wolf DA, Moyer MP. 1993. Rotating-wall vessel coculture
1217 of small intestine as a prelude to tissue modeling: aspects of simulated microgravity.
1218 Proc Soc Exp Biol Med 202:181-92.
1219 170. Straub TM, Honer zu Bentrup K, Orosz-Coghlan P, Dohnalkova A, Mayer BK,
1220 Bartholomew RA, Valdez CO, Bruckner-Lea CJ, Gerba CP, Abbaszadegan M,
1221 Nickerson CA. 2007. In vitro cell culture infectivity assay for human noroviruses. Emerg
1222 Infect Dis 13:396-403.
1223 171. Skardal A, Sarker SF, Crabbé A, Nickerson CA, Prestwich GD. 2010. The generation of
1224 3-D tissue models based on hyaluronan hydrogel-coated microcarriers within a rotating
1225 wall vessel bioreactor. Biomaterials 31:8426-8435.
1226 172. Barrila J, Yang J, Crabbe A, Sarker SF, Liu Y, Ott CM, Nelman-Gonzalez MA, Clemett
1227 SJ, Nydam SD, Forsyth RJ, Davis RR, Crucian BE, Quiriarte H, Roland KL, Brenneman
1228 K, Sams C, Loscher C, Nickerson CA. 2017. Three-dimensional organotypic co-culture
1229 model of intestinal epithelial cells and macrophages to study Salmonella enterica
1230 colonization patterns. NPJ Microgravity 3:10.
1231 173. De Weirdt R, Crabbe A, Roos S, Vollenweider S, Lacroix C, van Pijkeren JP, Britton RA,
1232 Sarker S, Van de Wiele T, Nickerson CA. 2012. Glycerol Supplementation Enhances L.
1233 reuteri's Protective Effect against S.Typhimurium Colonization in a 3-D Model of Colonic
1234 Epithelium. PLoS One 7:e37116.
1235 174. Goodwin TJ, Jessup JM, Wolf DA. 1992. Morphologic differentiation of colon carcinoma
1236 cell lines HT-29 and HT-29KM in rotating-wall vessels. In Vitro Cell Dev Biol 28A:47-60.
1237 175. Devarasetty M, Wang E, Soker S, Skardal A. 2017. Mesenchymal stem cells support
1238 growth and organization of host-liver colorectal-tumor organoids and possibly resistance
1239 to chemotherapy. Biofabrication 9:021002.
1240 176. Salerno-Goncalves R, Fasano A, Sztein MB. 2011. Engineering of a multicellular
1241 organotypic model of the human intestinal mucosa. Gastroenterology 141:e18-20.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

1242 177. Salerno-Goncalves R, Fasano A, Sztein MB. 2016. Development of a Multicellular
1243 Three-dimensional Organotypic Model of the Human Intestinal Mucosa Grown Under
1244 Microgravity. J Vis Exp doi:10.3791/54148.
1245 178. Salerno-Goncalves R, Safavie F, Fasano A, Sztein MB. 2016. Free and complexed-
1246 secretory immunoglobulin A triggers distinct intestinal epithelial cell responses. Clin Exp
1247 Immunol 185:338-47.
1248 179. Crabbe A, Liu Y, Matthijs N, Rigole P, De La Fuente-Nunez C, Davis R, Ledesma MA,
1249 Sarker S, Van Houdt R, Hancock RE, Coenye T, Nickerson CA. 2017. Antimicrobial
1250 efficacy against Pseudomonas aeruginosa biofilm formation in a three-dimensional lung
1251 epithelial model and the influence of fetal bovine serum. Sci Rep 7:43321.
1252 180. Crabbe A, Liu Y, Sarker SF, Bonenfant NR, Barrila J, Borg ZD, Lee JJ, Weiss DJ,
1253 Nickerson CA. 2015. Recellularization of decellularized lung scaffolds is enhanced by
1254 dynamic suspension culture. PLoS One 10:e0126846.
1255 181. Crabbe A, Sarker SF, Van Houdt R, Ott CM, Leys N, Cornelis P, Nickerson CA. 2011.
1256 Alveolar epithelium protects macrophages from quorum sensing-induced cytotoxicity in a
1257 three-dimensional co-culture model. Cell Microbiol 13:469-81.
1258 182. Cortiella J, Niles J, Cantu A, Brettler A, Pham A, Vargas G, Winston S, Wang J, Walls S,
1259 Nichols JE. 2010. Influence of acellular natural lung matrix on murine embryonic stem
1260 cell differentiation and tissue formation. Tissue Eng Part A 16:2565-80.
1261 183. Goodwin TJ, McCarthy M, Cohrs RJ, Kaufer BB. 2015. 3D tissue-like assemblies: A
1262 novel approach to investigate virus-cell interactions. Methods 90:76-84.
1263 184. Skardal A, Devarasetty M, Rodman C, Atala A, Soker S. 2015. Liver-Tumor Hybrid
1264 Organoids for Modeling Tumor Growth and Drug Response In Vitro. Ann Biomed Eng
1265 43:2361-73.

Accepted Manuscript Posted Online

1266 185. Khaoustov VI, Darlington GJ, Soriano HE, Krishnan B, Risin D, Pellis NR, Yoffe B. 1999.
1267 Induction of three-dimensional assembly of human liver cells by simulated microgravity.
1268 In Vitro Cell Dev Biol Anim 35:501-9.
1269 186. Prewett TL, Goodwin TJ, Spaulding GF. 1993. Three-dimensional modeling of T-24
1270 human bladder carcinoma cell line: A new simulated microgravity culture vessel. J Tiss
1271 Cult Meth 15:29-36.
1272 187. Ingram M, Techy GB, Saroufeem R, Yazan O, Narayan KS, Goodwin TJ, Spaulding GF.
1273 1997. Three-dimensional growth patterns of various human tumor cell lines in simulated
1274 microgravity of a NASA bioreactor. In Vitro Cellular & Developmental Biology - Animal
1275 33:459-466.
1276 188. Smith YC, Grande KK, Rasmussen SB, O'Brien AD. 2006. Novel three-dimensional
1277 organoid model for evaluation of the interaction of uropathogenic Escherichia coli with
1278 terminally differentiated human urothelial cells. Infect Immun 74:750-7.
1279 189. Laniewski P, Gomez A, Hire G, So M, Herbst-Kralovetz MM. 2017. Human Three-
1280 Dimensional Endometrial Epithelial Cell Model To Study Host Interactions with Vaginal
1281 Bacteria and Neisseria gonorrhoeae. Infect Immun 85.
1282 190. McGowin CL, Radtke AL, Abraham K, Martin DH, Herbst-Kralovetz M. 2013.
1283 Mycoplasma genitalium infection activates cellular host defense and inflammation
1284 pathways in a 3-dimensional human endocervical epithelial cell model. J Infect Dis
1285 207:1857-68.
1286 191. Doerflinger SY, Throop AL, Herbst-Kralovetz MM. 2014. Bacteria in the vaginal
1287 microbiome alter the innate immune response and barrier properties of the human
1288 vaginal epithelia in a species-specific manner. J Infect Dis 209:1989-99.
1289 192. Bursac N, Loo Y, Leong K, Tung L. 2007. Novel anisotropic engineered cardiac tissues:
1290 studies of electrical propagation. Biochemical and biophysical research communications
1291 361:847-853.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

Infection and Immunity

IAI

1292 193. Rungarunlert S, Klincumhom N, Bock I, Nemes C, Techakumphu M, Pirity MK, Dinnyes
1293 A. 2011. Enhanced cardiac differentiation of mouse embryonic stem cells by use of the
1294 slow-turning, lateral vessel (STLV) bioreactor. Biotechnology Letters 33:1565-1573.
1295 194. Papadaki M, Bursac N, Langer R, Merok J, Vunjak-Novakovic G, Freed LE. 2001.
1296 Tissue engineering of functional cardiac muscle: molecular, structural, and
1297 electrophysiological studies. Am J Physiol Heart Circ Physiol 280:H168-78.
1298 195. Margolis L, Hatfill S, Chuaqui R, Vocke C, Emmert-Buck M, Linehan WM, Duray PH.
1299 1999. Long term organ culture of human prostate tissue in a NASA-designed rotating
1300 wall bioreactor. J Urol 161:290-7.
1301 196. Rose MI, Brown DC, Pellis NR, Crisera CA, Colen KL, Longaker MT, Gittes GK. 1999.
1302 Effects of microgravity on the embryonic pancreas. In Vitro Cell Dev Biol Anim 35:560-3.
1303 197. Murray HE, Paget MB, Downing R. 2005. Preservation of glucose responsiveness in
1304 human islets maintained in a rotational cell culture system. Mol Cell Endocrinol 238:39-
1305 49.
1306 198. Lelkes PI, Galvan DL, Hayman GT, Goodwin TJ, Chatman DY, Cherian S, Garcia RM,
1307 Unsworth BR. 1998. Simulated microgravity conditions enhance differentiation of
1308 cultured PC12 cells towards the neuroendocrine phenotype. In Vitro Cell Dev Biol Anim
1309 34:316-25.
1310 199. Myers TA, Nickerson CA, Kaushal D, Ott CM, Höner zu Bentrup K, Ramamurthy R,
1311 Nelman-Gonzalez M, Pierson DL, Philipp MT. 2008. Closing the phenotypic gap
1312 between transformed neuronal cell lines in culture and untransformed neurons. Journal
1313 of Neuroscience Methods 174:31-41.
1314 200. Valmikinathan CM, Hoffman J, Yu X. 2011. Impact of Scaffold Micro and Macro
1315 Architecture on Schwann Cell Proliferation under Dynamic Conditions in a Rotating Wall
1316 Vessel Bioreactor. Mater Sci Eng C Mater Biol Appl 31:22-29.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity

Accepted Manuscript Posted Online
Infection and Immunity
IAI
Infection and Immunity

1317 201. Bramley JC, Drummond CG, Lennemann NJ, Good CA, Kim KS, Coyne CB. 2017. A
1318 Three-Dimensional Cell Culture System To Model RNA Virus Infections at the Blood-
1319 Brain Barrier. mSphere 2.
1320 202. Lei XH, Ning LN, Cao YJ, Liu S, Zhang SB, Qiu ZF, Hu HM, Zhang HS, Liu S, Duan EK.
1321 2011. NASA-approved rotary bioreactor enhances proliferation of human epidermal stem
1322 cells and supports formation of 3D epidermis-like structure. PLoS One 6:e26603.
1323 203. DiStefano T, Chen HY, Panebianco C, Kaya KD, Brooks MJ, Gieser L, Morgan NY,
1324 Pohida T, Swaroop A. 2018. Accelerated and Improved Differentiation of Retinal
1325 Organoids from Pluripotent Stem Cells in Rotating-Wall Vessel Bioreactors. Stem Cell
1326 Reports 10:300-313.
1327 204. Botchwey EA, Pollack SR, Levine EM, Laurencin CT. 2001. Bone tissue engineering in a
1328 rotating bioreactor using a microcarrier matrix system. Journal of biomedical materials
1329 research 55:242-253.
1330 205. Detamore MS, Athanasiou KA. 2005. Use of a Rotating Bioreactor toward Tissue
1331 Engineering the Temporomandibular Joint Disc. Tissue engineering 11:1188-1197.
1332 206. Yang X, Wang D, Hao J, Gong M, Arlet V, Balian G, Shen FH, Li XJ. 2011.
1333 Enhancement of matrix production and cell proliferation in human annulus cells under
1334 bioreactor culture. Tissue Eng Part A 17:1595-603.
1335 207. Rauh J, Milan F, Gunther KP, Stiehler M. 2011. Bioreactor systems for bone tissue
1336 engineering. Tissue Eng Part B Rev 17:263-80.
1337 208. Ulbrich C, Wehland M, Pietsch J, Aleshcheva G, Wise P, van Loon J, Magnusson N,
1338 Infanger M, Grosse J, Eilles C, Sundaresan A, Grimm D. 2014. The impact of simulated
1339 and real microgravity on bone cells and mesenchymal stem cells. Biomed Res Int
1340 2014:928507.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

1341 209. Duray PH, Yin SR, Ito Y, Bezrukov L, Cox C, Cho MS, Fitzgerald W, Dorward D,
1342 Zimmerberg J, Margolis L. 2005. Invasion of human tissue ex vivo by Borrelia
1343 burgdorferi. J Infect Dis 191:1747-54.
1344 210. Duke J, Daane E, Arizpe J, Montufar-Solis D. 1996. Chondrogenesis in aggregates of
1345 embryonic limb cells grown in a rotating wall vessel. Advances in space research : the
1346 official journal of the Committee on Space Research (COSPAR) 17:289-293.
1347 211. Darwin KH, Miller VL. 1999. Molecular basis of the interaction of Salmonella with the
1348 intestinal mucosa. Clin Microbiol Rev 12:405-28.
1349 212. Coombes BK, Coburn BA, Potter AA, Gomis S, Mirakhur K, Li Y, Finlay BB. 2005.
1350 Analysis of the Contribution of Salmonella Pathogenicity Islands 1 and 2 to Enteric
1351 Disease Progression Using a Novel Bovine Ileal Loop Model and a Murine Model of
1352 Infectious Enterocolitis. Infection and Immunity 73:7161-7169.
1353 213. Hapfelmeier S, Stecher B, Barthel M, Kremer M, Muller AJ, Heikenwalder M, Stallmach
1354 T, Hensel M, Pfeffer K, Akira S, Hardt WD. 2005. The Salmonella pathogenicity island
1355 (SPI)-2 and SPI-1 type III secretion systems allow Salmonella serovar typhimurium to
1356 trigger colitis via MyD88-dependent and MyD88-independent mechanisms. J Immunol
1357 174:1675-85.
1358 214. Hu Q, Coburn B, Deng W, Li Y, Shi X, Lan Q, Wang B, Coombes BK, Finlay BB. 2008.
1359 Salmonella enterica serovar Senftenberg human clinical isolates lacking SPI-1. J Clin
1360 Microbiol 46:1330-6.
1361 215. Kamada N, Chen GY, Inohara N, Nunez G. 2013. Control of pathogens and pathobionts
1362 by the gut microbiota. Nat Immunol 14:685-90.
1363 216. Kingsley RA, Msefula CL, Thomson NR, Kariuki S, Holt KE, Gordon MA, Harris D,
1364 Clarke L, Whitehead S, Sangal V, Marsh K, Achtman M, Molyneux ME, Cormican M,
1365 Parkhill J, MacLennan CA, Heyderman RS, Dougan G. 2009. Epidemic multiple drug

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

1366 resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have
1367 a distinct genotype. Genome Res 19:2279-87.
1368 217. Shieh JTC, Bergelson JM. 2002. Interaction with Decay-Accelerating Factor Facilitates
1369 Coxsackievirus B Infection of Polarized Epithelial Cells. Journal of Virology 76:9474-
1370 9480.
1371 218. Patel KP, Coyne CB, Bergelson JM. 2009. Dynamin- and lipid raft-dependent entry of
1372 decay-accelerating factor (DAF)-binding and non-DAF-binding coxsackieviruses into
1373 nonpolarized cells. J Virol 83:11064-77.
1374 219. Coyne CB, Bergelson JM. Virus-Induced Abl and Fyn Kinase Signals Permit
1375 Coxsackievirus Entry through Epithelial Tight Junctions. Cell 124:119-131.
1376 220. Pan J, Zhang L, Odenwald MA, Shen L, Turner JR, Bergelson JM. 2015. Expression of
1377 human decay-accelerating factor on intestinal epithelium of transgenic mice does not
1378 facilitate infection by the enteral route. J Virol 89:4311-8.
1379 221. Srinivasan B, Kolli AR, Esch MB, Abaci HE, Shuler ML, Hickman JJ. 2015. TEER
1380 measurement techniques for in vitro barrier model systems. J Lab Autom 20:107-26.
1381 222. Nickerson CA, Ott CM. 2004. A new dimension in modeling infectious disease. ASM
1382 News 70:169-175.
1383 223. Fatehullah A, Tan SH, Barker N. 2016. Organoids as an in vitro model of human
1384 development and disease. Nat Cell Biol 18:246-54.
1385 224. Flora AD, Teel LD, Smith MA, Sinclair JF, Melton-Celsa AR, O'Brien AD. 2013. Ricin
1386 Crosses Polarized Human Intestinal Cells and Intestines of Ricin-Gavaged Mice without
1387 Evident Damage and Then Disseminates to Mouse Kidneys. PLOS ONE 8:e69706.
1388 225. Bergmann S, Steinert M. 2015. From Single Cells to Engineered and Explanted Tissues:
1389 New Perspectives in Bacterial Infection Biology. Int Rev Cell Mol Biol 319:1-44.

Accepted Manuscript Posted Online

1390 226. Astashkina A, Grainger DW. 2014. Critical analysis of 3-D organoid in vitro cell culture
1391 models for high-throughput drug candidate toxicity assessments. Adv Drug Deliv Rev
1392 69-70:1-18.
1393 227. Shamir ER, Ewald AJ. 2014. Three-dimensional organotypic culture: experimental
1394 models of mammalian biology and disease. Nat Rev Mol Cell Biol 15:647-64.
1395 228. Bhat R, Bissell MJ. 2014. Of plasticity and specificity: dialectics of the microenvironment
1396 and macroenvironment and the organ phenotype. Wiley Interdiscip Rev Dev Biol 3:147-
1397 63.
1398 229. Bissell MJ. 2017. Goodbye flat biology - time for the 3rd and the 4th dimensions. J Cell
1399 Sci 130:3-5.
1400 230. Cruz-Acuna R, Quiros M, Farkas AE, Dedhia PH, Huang S, Siuda D, Garcia-Hernandez
1401 V, Miller AJ, Spence JR, Nusrat A, Garcia AJ. 2017. Synthetic hydrogels for human
1402 intestinal organoid generation and colonic wound repair. Nat Cell Biol 19:1326-1335.
1403 231. Bartfeld S. 2016. Modeling infectious diseases and host-microbe interactions in
1404 gastrointestinal organoids. Dev Biol 420:262-270.
1405 232. Bartfeld S, Clevers H. 2017. Stem cell-derived organoids and their application for
1406 medical research and patient treatment. Journal of Molecular Medicine 95:729-738.
1407 233. Finkbeiner SR, Spence JR. 2013. A gutsy task: generating intestinal tissue from human
1408 pluripotent stem cells. Dig Dis Sci 58:1176-84.
1409 234. Hill DR, Spence JR. 2017. Gastrointestinal Organoids: Understanding the Molecular
1410 Basis of the Host-Microbe Interface. Cell Mol Gastroenterol Hepatol 3:138-149.
1411 235. In JG, Foulke-Abel J, Estes MK, Zachos NC, Kovbasnjuk O, Donowitz M. 2016. Human
1412 mini-guts: new insights into intestinal physiology and host-pathogen interactions. Nat
1413 Rev Gastroenterol Hepatol 13:633-642.
1414 236. Zachos NC, Kovbasnjuk O, Foulke-Abel J, In J, Blutt SE, de Jonge HR, Estes MK,
1415 Donowitz M. 2016. Human Enteroids/Colonoids and Intestinal Organoids Functionally

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity
IAI
Infection and Immunity

Accepted Manuscript Posted Online

1416 Recapitulate Normal Intestinal Physiology and Pathophysiology. J Biol Chem 291:3759-
1417 66.
1418 237. Merker SR, Weitz J, Stange DE. 2016. Gastrointestinal organoids: How they gut it out.
1419 Developmental Biology 420:239-250.
1420 238. Dutta D, Clevers H. 2017. Organoid culture systems to study host-pathogen interactions.
1421 Curr Opin Immunol 48:15-22.
1422 239. Dedhia PH, Bertaux-Skeirik N, Zavros Y, Spence JR. 2016. Organoid Models of Human
1423 Gastrointestinal Development and Disease. Gastroenterology 150:1098-1112.
1424 240. Anonymous. 2018. Method of the Year 2017: Organoids. Nature Methods 15:1.
1425 241. Zhang YG, Wu S, Xia Y, Sun J. 2014. Salmonella-infected crypt-derived intestinal
1426 organoid culture system for host-bacterial interactions. Physiol Rep 2.
1427 242. Bhushal S, Wolfsmuller M, Selvakumar TA, Kemper L, Wirth D, Hornef MW, Hauser H,
1428 Koster M. 2017. Cell Polarization and Epigenetic Status Shape the Heterogeneous
1429 Response to Type III Interferons in Intestinal Epithelial Cells. Front Immunol 8:671.
1430 243. Davies JM, Santaolalla R, von Furstenberg RJ, Henning SJ, Abreu MT. 2015. The Viral
1431 Mimetic Polyinosinic:Polycytidylic Acid Alters the Growth Characteristics of Small
1432 Intestinal and Colonic Crypt Cultures. PLoS One 10:e0138531.
1433 244. Wilson SS, Tocchi A, Holly MK, Parks WC, Smith JG. 2014. A small intestinal organoid
1434 model of non-invasive enteric pathogen-epithelial cell interactions. Mucosal Immunol
1435 8:352-61.
1436 245. Yin Y, Bijvelds M, Dang W, Xu L, van der Eijk AA, Knipping K, Tuysuz N, Dekkers JF,
1437 Wang Y, de Jonge J, Sprengers D, van der Laan LJW, Beekman JM, ten Berge D,
1438 Metselaar HJ, de Jonge H, Koopmans MPG, Peppelenbosch MP, Pan Q. 2015.
1439 Modeling rotavirus infection and antiviral therapy using primary intestinal organoids.
1440 Antiviral Research 123:120-131.

Infection and Immunity
IAI
Infection and Immunity
Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

1441 246. Aladegbami B, Barron L, Bao J, Colasanti J, Erwin CR, Warner BW, Guo J. 2017.
1442 Epithelial cell specific Raptor is required for initiation of type 2 mucosal immunity in small
1443 intestine. Scientific Reports 7:5580.
1444 247. Cao L, Kuratnik A, Xu W, Gibson JD, Kolling Ft, Falcone ER, Ammar M, Van Heyst MD,
1445 Wright DL, Nelson CE, Giardina C. 2015. Development of intestinal organoids as tissue
1446 surrogates: cell composition and the epigenetic control of differentiation. Mol Carcinog
1447 54:189-202.
1448 248. Fischer JC, Bscheider M, Eisenkolb G, Lin CC, Wintges A, Otten V, Lindemans CA,
1449 Heidegger S, Rudelius M, Monette S, Porosnicu Rodriguez KA, Calafiore M, Liebermann
1450 S, Liu C, Lienenklaus S, Weiss S, Kalinke U, Ruland J, Peschel C, Shono Y, Docampo
1451 M, Velardi E, Jenq RR, Hanash AM, Dudakov JA, Haas T, van den Brink MRM, Poeck
1452 H. 2017. RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and
1453 immune-mediated tissue injury. Sci Transl Med 9.
1454 249. Foulke-Abel J, In J, Yin J, Zachos NC, Kovbasnjuk O, Estes MK, de Jonge H, Donowitz
1455 M. 2016. Human Enteroids as a Model of Upper Small Intestinal Ion Transport
1456 Physiology and Pathophysiology. Gastroenterology 150:638-649.e8.
1457 250. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH,
1458 Abo A, Kujala P, Peters PJ, Clevers H. 2009. Single Lgr5 stem cells build crypt-villus
1459 structures in vitro without a mesenchymal niche. Nature 459:262-5.
1460 251. Dekkers JF, Wiegerinck CL, de Jonge HR, Bronsveld I, Janssens HM, de Winter-de
1461 Groot KM, Brandsma AM, de Jong NWM, Bijvelds MJC, Scholte BJ, Nieuwenhuis EES,
1462 van den Brink S, Clevers H, van der Ent CK, Middendorp S, Beekman JM. 2013. A
1463 functional CFTR assay using primary cystic fibrosis intestinal organoids. Nature
1464 Medicine 19:939.
1465 252. de Lau W, Kujala P, Schneeberger K, Middendorp S, Li VS, Barker N, Martens A,
1466 Hofhuis F, DeKoter RP, Peters PJ, Nieuwenhuis E, Clevers H. 2012. Peyer's patch M

Infection and Immunity
IAI
Infection and Immunity
Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

1467 cells derived from Lgr5(+) stem cells require SpiB and are induced by RankL in cultured
1468 "miniguts". Mol Cell Biol 32:3639-47.
1469 253. McCracken KW, Howell JC, Wells JM, Spence JR. 2011. Generating human intestinal
1470 tissue from pluripotent stem cells in vitro. Nat Protoc 6:1920-8.
1471 254. Ootani A, Li X, Sangiorgi E, Ho QT, Ueno H, Toda S, Sugihara H, Fujimoto K, Weissman
1472 IL, Capecchi MR, Kuo CJ. 2009. Sustained in vitro intestinal epithelial culture within a
1473 Wnt-dependent stem cell niche. Nature Medicine 15:701.
1474 255. Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, Hoskins EE,
1475 Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF, Wells JM. 2011. Directed
1476 differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature
1477 470:105-9.
1478 256. Rodríguez-Colman MJ, Schewe M, Meerlo M, Stigter E, Gerrits J, Pras-Raves M,
1479 Sacchetti A, Hornsveld M, Oost KC, Snippert HJ, Verhoeven-Duif N, Fodde R, Burgering
1480 BMT. 2017. Interplay between metabolic identities in the intestinal crypt supports stem
1481 cell function. Nature 543:424.
1482 257. Workman MJ, Mahe MM, Trisno S, Poling HM, Watson CL, Sundaram N, Chang C-F,
1483 Schiesser J, Aubert P, Stanley EG, Elefanty AG, Miyaoka Y, Mandegar MA, Conklin BR,
1484 Neunlist M, Brugmann SA, Helmrath MA, Wells JM. 2016. Engineered human
1485 pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system.
1486 Nature Medicine 23:49.
1487 258. Forbester JL, Goulding D, Vallier L, Hannan N, Hale C, Pickard D, Mukhopadhyay S,
1488 Dougan G. 2015. Interaction of Salmonella enterica Serovar Typhimurium with Intestinal
1489 Organoids Derived from Human Induced Pluripotent Stem Cells. Infect Immun 83:2926-
1490 34.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity
IAI
Infection and Immunity

Accepted Manuscript Posted Online
Infection and Immunity
IAI
Infection and Immunity

1491 259. Engevik MA, Engevik KA, Yacyshyn MB, Wang J, Hassett DJ, Darien B, Yacyshyn BR,
1492 Worrell RT. 2015. Human Clostridium difficile infection: inhibition of NHE3 and
1493 microbiota profile. Am J Physiol Gastrointest Liver Physiol 308:G497-509.
1494 260. Engevik MA, Yacyshyn MB, Engevik KA, Wang J, Darien B, Hassett DJ, Yacyshyn BR,
1495 Worrell RT. 2015. Human Clostridium difficile infection: altered mucus production and
1496 composition. Am J Physiol Gastrointest Liver Physiol 308:G510-24.
1497 261. Karve SS, Pradhan S, Ward DV, Weiss AA. 2017. Intestinal organoids model human
1498 responses to infection by commensal and Shiga toxin producing Escherichia coli. PLoS
1499 One 12:e0178966.
1500 262. In J, Foulke-Abel J, Zachos NC, Hansen A-M, Kaper JB, Bernstein HD, Halushka M,
1501 Blutt S, Estes MK, Donowitz M, Kovbasnjuk O. 2016. Enterohemorrhagic Escherichia
1502 coli Reduces Mucus and Intermicrovillar Bridges in Human Stem Cell-Derived
1503 Colonoids. Cellular and Molecular Gastroenterology and Hepatology 2:48-62.e3.
1504 263. Leslie JL, Huang S, Opp JS, Nagy MS, Kobayashi M, Young VB, Spence JR. 2015.
1505 Persistence and toxin production by Clostridium difficile within human intestinal
1506 organoids result in disruption of epithelial paracellular barrier function. Infect Immun
1507 83:138-45.
1508 264. Tao L, Zhang J, Meraner P, Tovaglieri A, Wu X, Gerhard R, Zhang X, Stallcup WB, Miao
1509 J, He X, Hurdle JG, Breault DT, Brass AL, Dong M. 2016. Frizzled proteins are colonic
1510 epithelial receptors for C. difficile toxin B. Nature 538:350-355.
1511 265. Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, Van Houdt WJ,
1512 Pronk A, Van Gorp J, Siersema PD, Clevers H. 2011. Long-term expansion of epithelial
1513 organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.
1514 Gastroenterology 141:1762-72.
1515 266. Cristobal A, van den Toorn HWP, van de Wetering M, Clevers H, Heck AJR, Mohammed
1516 S. 2017. Personalized Proteome Profiles of Healthy and Tumor Human Colon Organoids

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

Infection and Immunity

IAI

1517 Reveal Both Individual Diversity and Basic Features of Colorectal Cancer. Cell Reports
1518 18:263-274.
1519 267. Yin Y, Wang Y, Dang W, Xu L, Su J, Zhou X, Wang W, Felczak K, van der Laan LJ,
1520 Pankiewicz KW, van der Eijk AA, Bijvelds M, Sprengers D, de Jonge H, Koopmans MP,
1521 Metselaar HJ, Peppelenbosch MP, Pan Q. 2016. Mycophenolic acid potently inhibits
1522 rotavirus infection with a high barrier to resistance development. Antiviral Res 133:41-9.
1523 268. Senger S, Ingano L, Freire R, Anselmo A, Zhu W, Sadreyev R, Walker WA, Fasano A.
1524 2018. Human Fetal-Derived Enterospheres Provide Insights on Intestinal Development
1525 and a Novel Model to Study Necrotizing Enterocolitis (NEC). Cell Mol Gastroenterol
1526 Hepatol 5:549-568.
1527 269. Nickerson KP, Senger S, Zhang Y, Lima R, Patel S, Ingano L, Flavahan WA, Kumar
1528 DKV, Fraser CM, Faherty CS, Sztein MB, Fiorentino M, Fasano A. 2018. Salmonella
1529 Typhi Colonization Provokes Extensive Transcriptional Changes Aimed at Evading Host
1530 Mucosal Immune Defense During Early Infection of Human Intestinal Tissue.
1531 EBioMedicine 31:92-109.
1532 270. Chen YW, Huang SX, de Carvalho A, Ho SH, Islam MN, Volpi S, Notarangelo LD,
1533 Ciancanelli M, Casanova JL, Bhattacharya J, Liang AF, Palermo LM, Porotto M,
1534 Moscona A, Snoeck HW. 2017. A three-dimensional model of human lung development
1535 and disease from pluripotent stem cells. Nat Cell Biol 19:542-549.
1536 271. Dye BR, Hill DR, Ferguson MA, Tsai YH, Nagy MS, Dyal R, Wells JM, Mayhew CN,
1537 Nattiv R, Klein OD, White ES, Deutsch GH, Spence JR. 2015. In vitro generation of
1538 human pluripotent stem cell derived lung organoids. Elife 4.
1539 272. Firth AL, Dargitz CT, Qualls SJ, Menon T, Wright R, Singer O, Gage FH, Khanna A,
1540 Verma IM. 2014. Generation of multiciliated cells in functional airway epithelia from
1541 human induced pluripotent stem cells. Proc Natl Acad Sci U S A 111:E1723-30.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity

Accepted Manuscript Posted Online

1542 273. Hegab AE, Arai D, Gao J, Kuroda A, Yasuda H, Ishii M, Naoki K, Soejima K, Betsuyaku
1543 T. 2015. Mimicking the niche of lung epithelial stem cells and characterization of several
1544 effectors of their in vitro behavior. Stem Cell Research 15:109-121.
1545 274. Nikolić MZ, Rawlins EL. 2017. Lung Organoids and Their Use To Study Cell-Cell
1546 Interaction. Current Pathobiology Reports 5:223-231.
1547 275. Shen Y, Chen L, Wang M, Lin D, Liang Z, Song P, Yuan Q, Tang H, Li W, Duan K, Liu
1548 B, Zhao G, Wang Y. 2017. Flagellar Hooks and Hook Protein FlgE Participate in Host
1549 Microbe Interactions at Immunological Level. Scientific Reports 7:1433.
1550 276. Bartfeld S, Bayram T, van de Wetering M, Huch M, Begthel H, Kujala P, Vries R, Peters
1551 PJ, Clevers H. 2015. In vitro expansion of human gastric epithelial stem cells and their
1552 responses to bacterial infection. Gastroenterology 148:126-136 e6.
1553 277. Mahe MM, Aihara E, Schumacher MA, Zavros Y, Montrose MH, Helmrath MA, Sato T,
1554 Shroyer NF. 2013. Establishment of Gastrointestinal Epithelial Organoids. Curr Protoc
1555 Mouse Biol 3:217-40.
1556 278. Bertaux-Skeirik N, Feng R, Schumacher MA, Li J, Mahe MM, Engevik AC, Javier JE,
1557 Peek RM, Jr., Ottemann K, Orian-Rousseau V, Boivin GP, Helmrath MA, Zavros Y.
1558 2015. CD44 plays a functional role in Helicobacter pylori-induced epithelial cell
1559 proliferation. PLoS Pathog 11:e1004663.
1560 279. McCracken KW, Cata EM, Crawford CM, Sinagoga KL, Schumacher M, Rockich BE,
1561 Tsai YH, Mayhew CN, Spence JR, Zavros Y, Wells JM. 2014. Modelling human
1562 development and disease in pluripotent stem-cell-derived gastric organoids. Nature
1563 516:400-4.
1564 280. Sigal M, Rothenberg ME, Logan CY, Lee JY, Honaker RW, Cooper RL, Passarelli B,
1565 Camorlinga M, Bouley DM, Alvarez G, Nusse R, Torres J, Amieva MR. 2015.
1566 Helicobacter pylori Activates and Expands Lgr5+ Stem Cells Through Direct
1567 Colonization of the Gastric Glands. Gastroenterology 148:1392-1404.e21.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

IAI Infection and Immunity

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

1568 281. McCracken KW, Aihara E, Martin B, Crawford CM, Broda T, Treguier J, Zhang X,
1569 Shannon JM, Montrose MH, Wells JM. 2017. Wnt/beta-catenin promotes gastric fundus
1570 specification in mice and humans. Nature 541:182-187.
1571 282. Schlaermann P, Toelle B, Berger H, Schmidt SC, Glanemann M, Ordemann J, Bartfeld
1572 S, Mollenkopf HJ, Meyer TF. 2016. A novel human gastric primary cell culture system for
1573 modelling Helicobacter pylori infection in vitro. Gut 65:202-13.
1574 283. Burkitt MD, Duckworth CA, Williams JM, Pritchard DM. 2017. Helicobacter pylori-
1575 induced gastric pathology: insights from in vivo and ex vivo models. Dis Model Mech
1576 10:89-104.
1577 284. Li ML, Aggeler J, Farson DA, Hatier C, Hassell J, Bissell MJ. 1987. Influence of a
1578 reconstituted basement membrane and its components on casein gene expression and
1579 secretion in mouse mammary epithelial cells. Proc Natl Acad Sci U S A 84:136-40.
1580 285. Vidi PA, Bissell MJ, Lelievre SA. 2013. Three-dimensional culture of human breast
1581 epithelial cells: the how and the why. Methods Mol Biol 945:193-219.
1582 286. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, Homfray T,
1583 Penninger JM, Jackson AP, Knoblich JA. 2013. Cerebral organoids model human brain
1584 development and microcephaly. Nature 501:373-9.
1585 287. Eiraku M, Watanabe K, Matsuo-Takasaki M, Kawada M, Yonemura S, Matsumura M,
1586 Wataya T, Nishiyama A, Muguruma K, Sasai Y. 2008. Self-organized formation of
1587 polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. Cell
1588 Stem Cell 3:519-32.
1589 288. Qian X, Nguyen Ha N, Song Mingxi M, Hadiono C, Ogden Sarah C, Hammack C, Yao B,
1590 Hamersky Gregory R, Jacob F, Zhong C, Yoon K-j, Jeang W, Lin L, Li Y, Thakor J, Berg
1591 Daniel A, Zhang C, Kang E, Chickering M, Nauen D, Ho C-Y, Wen Z, Christian
1592 Kimberly M, Shi P-Y, Maher Brady J, Wu H, Jin P, Tang H, Song H, Ming G-l. 2016.

1593 Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure.
1594 Cell 165:1238-1254.
1595 289. Huch M, Dorrell C, Boj SF, van Es JH, Li VSW, van de Wetering M, Sato T, Hamer K,
1596 Sasaki N, Finegold MJ, Haft A, Vries RG, Grompe M, Clevers H. 2013. In vitro
1597 expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature
1598 494:247.
1599 290. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang R-R, Ueno Y,
1600 Zheng Y-W, Koike N, Aoyama S, Adachi Y, Taniguchi H. 2013. Vascularized and
1601 functional human liver from an iPSC-derived organ bud transplant. Nature 499:481.
1602 291. Huch M, Bonfanti P, Boj SF, Sato T, Loomans CJM, van de Wetering M, Sojoodi M, Li
1603 VSW, Schuijers J, Gracanin A, Ringnalda F, Begthel H, Hamer K, Mulder J, van Es JH,
1604 de Koning E, Vries RGJ, Heimberg H, Clevers H. 2013. Unlimited in vitro expansion of
1605 adult bi‐potent pancreas progenitors through the Lgr5/R‐spondin axis. The EMBO
1606 Journal 32:2708-2721.
1607 292. Greggio C, De Franceschi F, Figueiredo-Larsen M, Gobaa S, Ranga A, Semb H, Lutolf
1608 M, Grapin-Botton A. 2013. Artificial three-dimensional niches deconstruct pancreas
1609 development in vitro. Development 140:4452-4462.
1610 293. Scanu T, Spaapen RM, Bakker JM, Pratap CB, Wu LE, Hofland I, Broeks A, Shukla VK,
1611 Kumar M, Janssen H, Song JY, Neefjes-Borst EA, te Riele H, Holden DW, Nath G,
1612 Neefjes J. 2015. Salmonella Manipulation of Host Signaling Pathways Provokes Cellular
1613 Transformation Associated with Gallbladder Carcinoma. Cell Host Microbe 17:763-74.
1614 294. Eiraku M, Takata N, Ishibashi H, Kawada M, Sakakura E, Okuda S, Sekiguchi K, Adachi
1615 T, Sasai Y. 2011. Self-organizing optic-cup morphogenesis in three-dimensional culture.
1616 Nature 472:51-6.

Accepted Manuscript Posted Online
Infection and Immunity
IAI
Infection and Immunity
Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

1617 295. Taguchi A, Kaku Y, Ohmori T, Sharmin S, Ogawa M, Sasaki H, Nishinakamura R. 2014.
1618 Redefining the in vivo origin of metanephric nephron progenitors enables generation of
1619 complex kidney structures from pluripotent stem cells. Cell Stem Cell 14:53-67.
1620 296. Karthaus Wouter R, Iaquinta Phillip J, Drost J, Gracanin A, van Boxtel R, Wongvipat J,
1621 Dowling Catherine M, Gao D, Begthel H, Sachs N, Vries Robert GJ, Cuppen E, Chen Y,
1622 Sawyers Charles L, Clevers Hans C. 2014. Identification of Multipotent Luminal
1623 Progenitor Cells in Human Prostate Organoid Cultures. Cell 159:163-175.
1624 297. Chua CW, Shibata M, Lei M, Toivanen R, Barlow LJ, Bergren Sarah K, Badani KK,
1625 McKiernan JM, Benson MC, Hibshoosh H, Shen MM. 2014. Single luminal epithelial
1626 progenitors can generate prostate organoids in culture. Nature Cell Biology 16:951.
1627 298. Zhu Y, Yang Y, Guo J, Dai Y, Ye L, Qiu J, Zeng Z, Wu X, Xing Y, Long X, Wu X, Ye L,
1628 Wang S, Li H. 2017. Ex vivo 2D and 3D HSV-2 infection model using human normal
1629 vaginal epithelial cells. Oncotarget 8:15267-15282.
1630 299. Kessler M, Hoffmann K, Brinkmann V, Thieck O, Jackisch S, Toelle B, Berger H,
1631 Mollenkopf HJ, Mangler M, Sehouli J, Fotopoulou C, Meyer TF. 2015. The Notch and
1632 Wnt pathways regulate stemness and differentiation in human fallopian tube organoids.
1633 Nat Commun 6:8989.
1634 300. Ghaedi M, Calle EA, Mendez JJ, Gard AL, Balestrini J, Booth A, Bove PF, Gui L, White
1635 ES, Niklason LE. 2013. Human iPS cell-derived alveolar epithelium repopulates lung
1636 extracellular matrix. J Clin Invest 123:4950-62.
1637 301. Finkbeiner SR, Freeman JJ, Wieck MM, El-Nachef W, Altheim CH, Tsai YH, Huang S,
1638 Dyal R, White ES, Grikscheit TC, Teitelbaum DH, Spence JR. 2015. Generation of
1639 tissue-engineered small intestine using embryonic stem cell-derived human intestinal
1640 organoids. Biol Open 4:1462-72.
1641 302. Quantius J, Schmoldt C, Vazquez-Armendariz AI, Becker C, El Agha E, Wilhelm J, Morty
1642 RE, Vadasz I, Mayer K, Gattenloehner S, Fink L, Matrosovich M, Li X, Seeger W,

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

1643 Lohmeyer J, Bellusci S, Herold S. 2016. Influenza Virus Infects Epithelial
1644 Stem/Progenitor Cells of the Distal Lung: Impact on Fgfr2b-Driven Epithelial Repair.
1645 PLoS Pathog 12:e1005544.
1646 303. Al Shammari B, Shiomi T, Tezera L, Bielecka MK, Workman V, Sathyamoorthy T, Mauri
1647 F, Jayasinghe SN, Robertson BD, D'Armiento J, Friedland JS, Elkington PT. 2015. The
1648 Extracellular Matrix Regulates Granuloma Necrosis in Tuberculosis. J Infect Dis
1649 212:463-73.
1650 304. Clevers H. 2016. Modeling Development and Disease with Organoids. Cell 165:1586-97.
1651 305. Lancaster MA, Knoblich JA. 2014. Organogenesis in a dish: modeling development and
1652 disease using organoid technologies. Science 345:1247125.
1653 306. Bissell MJ, Labarge MA. 2005. Context, tissue plasticity, and cancer: are tumor stem
1654 cells also regulated by the microenvironment? Cancer Cell 7:17-23.
1655 307. Chingwaru W, Glashoff RH, Vidmar J, Kapewangolo P, Sampson SL. 2016. Mammalian
1656 cell cultures as models for Mycobacterium tuberculosis–human immunodeficiency virus
1657 (HIV) interaction studies: A review. Asian Pacific Journal of Tropical Medicine 9:832-838.
1658 308. Dutta D, Heo I, Clevers H. 2017. Disease Modeling in Stem Cell-Derived 3D Organoid
1659 Systems. Trends Mol Med 23:393-410.
1660 309. Haber AL, Biton M, Rogel N, Herbst RH, Shekhar K, Smillie C, Burgin G, Delorey TM,
1661 Howitt MR, Katz Y, Tirosh I, Beyaz S, Dionne D, Zhang M, Raychowdhury R, Garrett
1662 WS, Rozenblatt-Rosen O, Shi HN, Yilmaz O, Xavier RJ, Regev A. 2017. A single-cell
1663 survey of the small intestinal epithelium. Nature 551:333-339.
1664 310. Foulke-Abel J, In J, Kovbasnjuk O, Zachos NC, Ettayebi K, Blutt SE, Hyser JM, Zeng
1665 XL, Crawford SE, Broughman JR, Estes MK, Donowitz M. 2014. Human enteroids as an
1666 ex-vivo model of host-pathogen interactions in the gastrointestinal tract. Exp Biol Med
1667 (Maywood) 239:1124-34.

Infection and Immunity
IAI
Infection and Immunity
Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

1668 311. Lukovac S, Belzer C, Pellis L, Keijser BJ, de Vos WM, Montijn RC, Roeselers G. 2014.
1669 Differential Modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of
1670 Host Peripheral Lipid Metabolism and Histone Acetylation in Mouse Gut Organoids.
1671 mBio 5.
1672 312. Naito T, Mulet C, De Castro C, Molinaro A, Saffarian A, Nigro G, Bérard M, Clerc M,
1673 Pedersen AB, Sansonetti PJ, Pédron T. 2017. Lipopolysaccharide from Crypt-Specific
1674 Core Microbiota Modulates the Colonic Epithelial Proliferation-to-Differentiation Balance.
1675 mBio 8.
1676 313. Nigro G, Rossi R, Commere PH, Jay P, Sansonetti PJ. 2014. The cytosolic bacterial
1677 peptidoglycan sensor Nod2 affords stem cell protection and links microbes to gut
1678 epithelial regeneration. Cell Host Microbe 15:792-8.
1679 314. Noel G, Baetz NW, Staab JF, Donowitz M, Kovbasnjuk O, Pasetti MF, Zachos NC. 2017.
1680 A primary human macrophage-enteroid co-culture model to investigate mucosal gut
1681 physiology and host-pathogen interactions. Sci Rep 7:45270.
1682 315. Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, Tenge VR, Neill
1683 FH, Blutt SE, Zeng XL, Qu L, Kou B, Opekun AR, Burrin D, Graham DY, Ramani S,
1684 Atmar RL, Estes MK. 2016. Replication of human noroviruses in stem cell-derived
1685 human enteroids. Science 353:1387-1393.
1686 316. Finkbeiner SR, Zeng XL, Utama B, Atmar RL, Shroyer NF, Estes MK. 2012. Stem cell-
1687 derived human intestinal organoids as an infection model for rotaviruses. MBio
1688 3:e00159-12.
1689 317. Huang L, Hou Q, Ye L, Yang Q, Yu Q. 2017. Crosstalk between H9N2 avian influenza
1690 virus and crypt-derived intestinal organoids. Veterinary Research 48:71.
1691 318. Zhang D, Tan M, Zhong W, Xia M, Huang P, Jiang X. 2017. Human intestinal organoids
1692 express histo-blood group antigens, bind norovirus VLPs, and support limited norovirus
1693 replication. Sci Rep 7:12621.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity IAI Infection and Immunity

Accepted Manuscript Posted Online

Infection and Immunity

IAI

1694 319. Zhou J, Li C, Zhao G, Chu H, Wang D, Yan HH-N, Poon VK-M, Wen L, Wong BH-Y,
1695 Zhao X, Chiu MC, Yang D, Wang Y, Au-Yeung RKH, Chan IH-Y, Sun S, Chan JF-W, To
1696 KK-W, Memish ZA, Corman VM, Drosten C, Hung IF-N, Zhou Y, Leung SY, Yuen K-Y.
1697 2017. Human intestinal tract serves as an alternative infection route for Middle East
1698 respiratory syndrome coronavirus. Science Advances 3.

1699 320. Burger E, Araujo A, Lopez-Yglesias A, Rajala MW, Geng L, Levine B, Hooper LV,
1700 Burstein E, Yarovinsky F. 2018. Loss of Paneth Cell Autophagy Causes Acute
1701 Susceptibility to Toxoplasma gondii-Mediated Inflammation. Cell Host Microbe
1702 doi:10.1016/j.chom.2018.01.001.

1703 321. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A,
1704 Korving J, Begthel H, Peters PJ, Clevers H. 2007. Identification of stem cells in small
1705 intestine and colon by marker gene Lgr5. Nature 449:1003-7.

1706 322. Jung P, Sato T, Merlos-Suarez A, Barriga FM, Iglesias M, Rossell D, Auer H, Gallardo
1707 M, Blasco MA, Sancho E, Clevers H, Batlle E. 2011. Isolation and in vitro expansion of
1708 human colonic stem cells. Nat Med 17:1225-7.

1709 323. Hannan NR, Fordham RP, Syed YA, Moignard V, Berry A, Bautista R, Hanley NA,
1710 Jensen KB, Vallier L. 2013. Generation of multipotent foregut stem cells from human
1711 pluripotent stem cells. Stem Cell Reports 1:293-306.

1712 324. Kleinman HK, Martin GR. 2005. Matrigel: basement membrane matrix with biological
1713 activity. Semin Cancer Biol 15:378-86.

1714 325. Orkin RW, Gehron P, McGoodwin EB, Martin GR, Valentine T, Swarm R. 1977. A
1715 murine tumor producing a matrix of basement membrane. J Exp Med 145:204-20.

1716 326. Stelzner M, Helmrath M, Dunn JC, Henning SJ, Houchen CW, Kuo C, Lynch J, Li L,
1717 Magness ST, Martin MG, Wong MH, Yu J, Consortium NIHISC. 2012. A nomenclature
1718 for intestinal in vitro cultures. Am J Physiol Gastrointest Liver Physiol 302:G1359-63.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity

Accepted Manuscript Posted Online

1719 327. Nossol C, Diesing AK, Walk N, Faber-Zuschratter H, Hartig R, Post A, Kluess J,
1720 Rothkotter HJ, Kahlert S. 2011. Air-liquid interface cultures enhance the oxygen supply
1721 and trigger the structural and functional differentiation of intestinal porcine epithelial cells
1722 (IPEC). Histochem Cell Biol 136:103-15.
1723 328. Drummond CG, Bolock AM, Ma C, Luke CJ, Good M, Coyne CB. 2017. Enteroviruses
1724 infect human enteroids and induce antiviral signaling in a cell lineage-specific manner.
1725 Proc Natl Acad Sci U S A 114:1672-1677.
1726 329. van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Houdt
1727 W, van Gorp J, Taylor-Weiner A, Kester L, McLaren-Douglas A, Blokker J, Jaksani S,
1728 Bartfeld S, Volckman R, van Sluis P, Li VS, Seepo S, Sekhar Pedamallu C, Cibulskis K,
1729 Carter SL, McKenna A, Lawrence MS, Lichtenstein L, Stewart C, Koster J, Versteeg R,
1730 van Oudenaarden A, Saez-Rodriguez J, Vries RG, Getz G, Wessels L, Stratton MR,
1731 McDermott U, Meyerson M, Garnett MJ, Clevers H. 2015. Prospective derivation of a
1732 living organoid biobank of colorectal cancer patients. Cell 161:933-45.
1733 330. Kingwell K. 2016. 3D cell technologies head to the R&D assembly line. Nat Rev Drug
1734 Discov 16:6-7.
1735 331. Noordhoek J, Gulmans V, van der Ent K, Beekman JM. 2016. Intestinal organoids and
1736 personalized medicine in cystic fibrosis: a successful patient-oriented research
1737 collaboration. Curr Opin Pulm Med 22:610-6.
1738 332. Ohno H, Kanaya T, Williams IR. 2012. M cell differentiation: distinct lineage or
1739 phenotypic transition? Salmonella provides answers. Cell Host Microbe 12:607-9.
1740 333. Tahoun A, Mahajan S, Paxton E, Malterer G, Donaldson David S, Wang D, Tan A,
1741 Gillespie Trudi L, O'Shea M, Roe Andrew J, Shaw Darren J, Gally David L, Lengeling A,
1742 Mabbott Neil A, Haas J, Mahajan A. 2012. Salmonella Transforms Follicle-Associated
1743 Epithelial Cells into M Cells to Promote Intestinal Invasion. Cell Host & Microbe 12:645-
1744 656.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity IAI Infection and Immunity

Accepted Manuscript Posted Online

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

1745 334. Kernéis S, Bogdanova A, Kraehenbuhl J-P, Pringault E. 1997. Conversion by Peyer's
1746 Patch Lymphocytes of Human Enterocytes into M Cells that Transport Bacteria. Science
1747 277:949-952.

1748 335. Kasendra M, Tovaglieri A, Sontheimer-Phelps A, Jalili-Firoozinezhad S, Bein A,
1749 Chalkiadaki A, Scholl W, Zhang C, Rickner H, Richmond CA, Li H, Breault DT, Ingber
1750 DE. 2018. Development of a primary human Small Intestine-on-a-Chip using biopsy-
1751 derived organoids. Scientific Reports 8:2871.

1752 336. Bhatia SN, Ingber DE. 2014. Microfluidic organs-on-chips. Nat Biotechnol 32:760-72.

1753 337. Benam KH, Dauth S, Hassell B, Herland A, Jain A, Jang KJ, Karalis K, Kim HJ,
1754 MacQueen L, Mahmoodian R, Musah S, Torisawa YS, van der Meer AD, Villenave R,
1755 Yadid M, Parker KK, Ingber DE. 2015. Engineered in vitro disease models. Annu Rev
1756 Pathol 10:195-262.

1757 338. Selimovic S, Dokmeci MR, Khademhosseini A. 2013. Organs-on-a-chip for drug
1758 discovery. Curr Opin Pharmacol 13:829-33.

1759 339. Huh D, Torisawa YS, Hamilton GA, Kim HJ, Ingber DE. 2012. Microengineered
1760 physiological biomimicry: organs-on-chips. Lab Chip 12:2156-64.

1761 340. Esch EW, Bahinski A, Huh D. 2015. Organs-on-chips at the frontiers of drug discovery.
1762 Nat Rev Drug Discov 14:248-60.

1763 341. Kim HJ, Huh D, Hamilton G, Ingber DE. 2012. Human gut-on-a-chip inhabited by
1764 microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip
1765 12:2165-74.

1766 342. Kim HJ, Ingber DE. 2013. Gut-on-a-Chip microenvironment induces human intestinal
1767 cells to undergo villus differentiation. Integr Biol (Camb) 5:1130-40.

1768 343. Kim HJ, Li H, Collins JJ, Ingber DE. 2016. Contributions of microbiome and mechanical
1769 deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-
1770 chip. Proc Natl Acad Sci U S A 113:E7-15.

Accepted Manuscript Posted Online

1771 344. Villenave R, Wales SQ, Hamkins-Indik T, Papafragkou E, Weaver JC, Ferrante TC,
1772 Bahinski A, Elkins CA, Kulka M, Ingber DE. 2017. Human Gut-On-A-Chip Supports
1773 Polarized Infection of Coxsackie B1 Virus In Vitro. PLoS One 12:e0169412.
1774 345. Huh D, Hamilton GA, Ingber DE. 2011. From 3D cell culture to organs-on-chips. Trends
1775 Cell Biol 21:745-54.
1776 346. Huh D, Kim HJ, Fraser JP, Shea DE, Khan M, Bahinski A, Hamilton GA, Ingber DE.
1777 2013. Microfabrication of human organs-on-chips. Nat Protoc 8:2135-57.
1778 347. Folch A, Toner M. 2000. Microengineering of cellular interactions. Annu Rev Biomed
1779 Eng 2:227-56.
1780 348. Khademhosseini A, Langer R, Borenstein J, Vacanti JP. 2006. Microscale technologies
1781 for tissue engineering and biology. Proc Natl Acad Sci U S A 103:2480-7.
1782 349. Whitesides GM, Ostuni E, Takayama S, Jiang X, Ingber DE. 2001. Soft lithography in
1783 biology and biochemistry. Annu Rev Biomed Eng 3:335-73.
1784 350. Whitesides GM. 2006. The origins and the future of microfluidics. Nature 442:368-73.
1785 351. Halldorsson S, Lucumi E, Gomez-Sjoberg R, Fleming RM. 2015. Advantages and
1786 challenges of microfluidic cell culture in polydimethylsiloxane devices. Biosens
1787 Bioelectron 63:218-31.
1788 352. Sackmann EK, Fulton AL, Beebe DJ. 2014. The present and future role of microfluidics
1789 in biomedical research. Nature 507:181-9.
1790 353. Yi H-G, Lee H, Cho D-W. 2017. 3D Printing of Organs-On-Chips. Bioengineering 4:10.
1791 354. Henry OYF, Villenave R, Cronce MJ, Leineweber WD, Benz MA, Ingber DE. 2017.
1792 Organs-on-chips with integrated electrodes for trans-epithelial electrical resistance
1793 (TEER) measurements of human epithelial barrier function. Lab Chip 17:2264-2271.
1794 355. Kim J, Hegde M, Jayaraman A. 2010. Co-culture of epithelial cells and bacteria for
1795 investigating host-pathogen interactions. Lab Chip 10:43-50.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

IAI Infection and Immunity

Accepted Manuscript Posted Online

1796 356. Esch MB, Sung JH, Yang J, Yu C, Yu J, March JC, Shuler ML. 2012. On chip porous
1797 polymer membranes for integration of gastrointestinal tract epithelium with microfluidic
1798 'body-on-a-chip' devices. Biomed Microdevices 14:895-906.
1799 357. Mahler GJ, Esch MB, Glahn RP, Shuler ML. 2009. Characterization of a gastrointestinal
1800 tract microscale cell culture analog used to predict drug toxicity. Biotechnology and
1801 Bioengineering 104:193-205.
1802 358. Huh D, Fujioka H, Tung YC, Futai N, Paine R, 3rd, Grotberg JB, Takayama S. 2007.
1803 Acoustically detectable cellular-level lung injury induced by fluid mechanical stresses in
1804 microfluidic airway systems. Proc Natl Acad Sci U S A 104:18886-91.
1805 359. Huh D, Leslie DC, Matthews BD, Fraser JP, Jurek S, Hamilton GA, Thorneloe KS,
1806 McAlexander MA, Ingber DE. 2012. A human disease model of drug toxicity-induced
1807 pulmonary edema in a lung-on-a-chip microdevice. Sci Transl Med 4:159ra147.
1808 360. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. 2010.
1809 Reconstituting organ-level lung functions on a chip. Science 328:1662-8.
1810 361. Huh DD. 2015. A human breathing lung-on-a-chip. Ann Am Thorac Soc 12 Suppl 1:S42-
1811 4.
1812 362. Tavana H, Zamankhan P, Christensen PJ, Grotberg JB, Takayama S. 2011. Epithelium
1813 damage and protection during reopening of occluded airways in a physiologic
1814 microfluidic pulmonary airway model. Biomed Microdevices 13:731-42.
1815 363. Kane BJ, Zinner MJ, Yarmush ML, Toner M. 2006. Liver-specific functional studies in a
1816 microfluidic array of primary mammalian hepatocytes. Anal Chem 78:4291-8.
1817 364. Lee PJ, Hung PJ, Lee LP. 2007. An artificial liver sinusoid with a microfluidic endothelial-
1818 like barrier for primary hepatocyte culture. Biotechnol Bioeng 97:1340-6.
1819 365. Chao P, Maguire T, Novik E, Cheng KC, Yarmush ML. 2009. Evaluation of a microfluidic
1820 based cell culture platform with primary human hepatocytes for the prediction of hepatic
1821 clearance in human. Biochem Pharmacol 78:625-32.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity IAI Infection and Immunity

Accepted Manuscript Posted Online

1822 366. Novik E, Maguire TJ, Chao P, Cheng KC, Yarmush ML. 2010. A microfluidic hepatic
1823 coculture platform for cell-based drug metabolism studies. Biochem Pharmacol 79:1036-
1824 44.
1825 367. Legendre A, Baudoin R, Alberto G, Paullier P, Naudot M, Bricks T, Brocheton J, Jacques
1826 S, Cotton J, Leclerc E. 2013. Metabolic characterization of primary rat hepatocytes
1827 cultivated in parallel microfluidic biochips. J Pharm Sci 102:3264-76.
1828 368. Cheng S, Prot JM, Leclerc E, Bois FY. 2012. Zonation related function and ubiquitination
1829 regulation in human hepatocellular carcinoma cells in dynamic vs. static culture
1830 conditions. BMC Genomics 13:54.
1831 369. Sivaraman A, Leach JK, Townsend S, Iida T, Hogan BJ, Stolz DB, Fry R, Samson LD,
1832 Tannenbaum SR, Griffith LG. 2005. A microscale in vitro physiological model of the liver:
1833 predictive screens for drug metabolism and enzyme induction. Curr Drug Metab 6:569-
1834 91.
1835 370. Toh YC, Lim TC, Tai D, Xiao G, van Noort D, Yu H. 2009. A microfluidic 3D hepatocyte
1836 chip for drug toxicity testing. Lab Chip 9:2026-35.
1837 371. Baudoin R, Griscom L, Monge M, Legallais C, Leclerc E. 2007. Development of a renal
1838 microchip for in vitro distal tubule models. Biotechnol Prog 23:1245-53.
1839 372. Jang KJ, Mehr AP, Hamilton GA, McPartlin LA, Chung S, Suh KY, Ingber DE. 2013.
1840 Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity
1841 assessment. Integr Biol (Camb) 5:1119-29.
1842 373. Jang KJ, Suh KY. 2010. A multi-layer microfluidic device for efficient culture and analysis
1843 of renal tubular cells. Lab Chip 10:36-42.
1844 374. Agarwal A, Goss JA, Cho A, McCain ML, Parker KK. 2013. Microfluidic heart on a chip
1845 for higher throughput pharmacological studies. Lab Chip 13:3599-608.

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity IAI Infection and Immunity

Accepted Manuscript Posted Online

1846 375. Khanal G, Chung K, Solis-Wever X, Johnson B, Pappas D. 2011. Ischemia/reperfusion
1847 injury of primary porcine cardiomyocytes in a low-shear microfluidic culture and analysis
1848 device. Analyst 136:3519-26.
1849 376. Grosberg A, Alford PW, McCain ML, Parker KK. 2011. Ensembles of engineered cardiac
1850 tissues for physiological and pharmacological study: heart on a chip. Lab Chip 11:4165-
1851 73.
1852 377. Cheng W, Klauke N, Sedgwick H, Smith GL, Cooper JM. 2006. Metabolic monitoring of
1853 the electrically stimulated single heart cell within a microfluidic platform. Lab on a Chip
1854 6:1424-1431.
1855 378. Giridharan GA, Nguyen M-D, Estrada R, Parichehreh V, Hamid T, Ismahil MA, Prabhu
1856 SD, Sethu P. 2010. Microfluidic Cardiac Cell Culture Model (μCCCM). Analytical
1857 Chemistry 82:7581-7587.
1858 379. Puleo CM, McIntosh Ambrose W, Takezawa T, Elisseeff J, Wang TH. 2009. Integration
1859 and application of vitrified collagen in multilayered microfluidic devices for corneal
1860 microtissue culture. Lab Chip 9:3221-7.
1861 380. O'Neill AT, Monteiro-Riviere NA, Walker GM. 2008. Characterization of microfluidic
1862 human epidermal keratinocyte culture. Cytotechnology 56:197-207.
1863 381. Xiao RR, Zeng WJ, Li YT, Zou W, Wang L, Pei XF, Xie M, Huang WH. 2013.
1864 Simultaneous generation of gradients with gradually changed slope in a microfluidic
1865 device for quantifying axon response. Anal Chem 85:7842-50.
1866 382. Tsantoulas C, Farmer C, Machado P, Baba K, McMahon SB, Raouf R. 2013. Probing
1867 Functional Properties of Nociceptive Axons Using a Microfluidic Culture System. PLOS
1868 ONE 8:e80722.
1869 383. Shi M, Majumdar D, Gao Y, Brewer BM, Goodwin CR, McLean JA, Li D, Webb DJ.
1870 2013. Glia co-culture with neurons in microfluidic platforms promotes the formation and
1871 stabilization of synaptic contacts. Lab Chip 13:3008-21.

Infection and Immunity
IAI
Infection and Immunity
Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

1872 384. Shayan G, Shuler ML, Lee KH. 2011. The effect of astrocytes on the induction of barrier
1873 properties in aortic endothelial cells. Biotechnol Prog 27:1137-45.
1874 385. Park SH, Sim WY, Min BH, Yang SS, Khademhosseini A, Kaplan DL. 2012. Chip-based
1875 comparison of the osteogenesis of human bone marrow- and adipose tissue-derived
1876 mesenchymal stem cells under mechanical stimulation. PLoS One 7:e46689.
1877 386. Zhang Y, Gazit Z, Pelled G, Gazit D, Vunjak-Novakovic G. 2011. Patterning
1878 osteogenesis by inducible gene expression in microfluidic culture systems. Integr Biol
1879 (Camb) 3:39-47.
1880 387. Xiao S, Coppeta JR, Rogers HB, Isenberg BC, Zhu J, Olalekan SA, McKinnon KE, Dokic
1881 D, Rashedi AS, Haisenleder DJ, Malpani SS, Arnold-Murray CA, Chen K, Jiang M, Bai L,
1882 Nguyen CT, Zhang J, Laronda MM, Hope TJ, Maniar KP, Pavone ME, Avram MJ, Sefton
1883 EC, Getsios S, Burdette JE, Kim JJ, Borenstein JT, Woodruff TK. 2017. A microfluidic
1884 culture model of the human reproductive tract and 28-day menstrual cycle. Nature
1885 Communications 8:14584.
1886 388. Griep LM, Wolbers F, de Wagenaar B, ter Braak PM, Weksler BB, Romero IA, Couraud
1887 PO, Vermes I, van der Meer AD, van den Berg A. 2013. BBB on chip: microfluidic
1888 platform to mechanically and biochemically modulate blood-brain barrier function.
1889 Biomed Microdevices 15:145-50.
1890 389. Booth R, Kim H. 2012. Characterization of a microfluidic in vitro model of the blood-brain
1891 barrier (muBBB). Lab Chip 12:1784-92.
1892 390. van der Helm MW, van der Meer AD, Eijkel JC, van den Berg A, Segerink LI. 2016.
1893 Microfluidic organ-on-chip technology for blood-brain barrier research. Tissue Barriers
1894 4:e1142493.
1895 391. Liu MC, Shih HC, Wu JG, Weng TW, Wu CY, Lu JC, Tung YC. 2013. Electrofluidic
1896 pressure sensor embedded microfluidic device: a study of endothelial cells under
1897 hydrostatic pressure and shear stress combinations. Lab Chip 13:1743-53.

Accepted Manuscript Posted Online

Infection and Immunity

IAI

1898 392. Hasenberg T, Muhleder S, Dotzler A, Bauer S, Labuda K, Holnthoner W, Redl H,
1899 Lauster R, Marx U. 2015. Emulating human microcapillaries in a multi-organ-chip
1900 platform. J Biotechnol 216:1-10.

1901 393. Shin M, Matsuda K, Ishii O, Terai H, Kaazempur-Mofrad M, Borenstein J, Detmar M,
1902 Vacanti JP. 2004. Endothelialized networks with a vascular geometry in microfabricated
1903 poly(dimethyl siloxane). Biomed Microdevices 6:269-78.

1904 394. van der Meer AD, Orlova VV, ten Dijke P, van den Berg A, Mummery CL. 2013. Three-
1905 dimensional co-cultures of human endothelial cells and embryonic stem cell-derived
1906 pericytes inside a microfluidic device. Lab Chip 13:3562-8.

1907 395. Wikswo JP. 2014. The relevance and potential roles of microphysiological systems in
1908 biology and medicine. Exp Biol Med (Maywood) 239:1061-72.

1909 396. Stucki AO, Stucki JD, Hall SR, Felder M, Mermoud Y, Schmid RA, Geiser T, Guenat OT.
1910 2015. A lung-on-a-chip array with an integrated bio-inspired respiration mechanism. Lab
1911 Chip 15:1302-10.

1912 397. Benam KH, Villenave R, Lucchesi C, Varone A, Hubeau C, Lee HH, Alves SE, Salmon
1913 M, Ferrante TC, Weaver JC, Bahinski A, Hamilton GA, Ingber DE. 2016. Small airway-
1914 on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat
1915 Methods 13:151-7.

1916 398. Abaci HE, Shuler ML. 2015. Human-on-a-chip design strategies and principles for
1917 physiologically based pharmacokinetics/pharmacodynamics modeling. Integr Biol
1918 (Camb) 7:383-91.

1919
1920

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Infection and Immunity

Accepted Manuscript Posted Online
Infection and Immunity
IAI

1921 **Author Bios**

1922
1923
1924 **Jennifer Barrila** is an Assistant Research Professor at the Biodesign Institute, Arizona State
1925 University. She received her B.S. in Biochemistry in 2002 from Syracuse University. In 2008 she
1926 received her Ph.D. in Biology from Johns Hopkins University, where she structurally
1927 characterized the SARS coronavirus main protease to facilitate structure-based drug design.
1928 Her postdoctoral work at the Biodesign Institute used innovative culture systems to investigate
1929 how biomechanical forces regulate host and pathogen responses during infection. In 2010 she
1930 was promoted to Assistant Research Scientist and in 2013 to Assistant Research Professor.
1931 Her current research involves the development and application of multicellular 3-D models of
1932 human intestine to investigate the role of cellular biomechanics in host-pathogen-microbiota
1933 interactions. Her biomedical research has flown on several NASA spaceflight missions to the
1934 International Space Station to study the influence of biophysical forces on infection. In 2014 she
1935 received the Thora W. Halstead Young Investigator's Award.
1936
1937
1938 **Aurélie Crabbé** obtained her PhD in Bioscience Engineering at the Vrije Universiteit Brussel,
1939 Belgium. During her PhD she received a fellowship of the Belgian American Educational
1940 Foundation to perform research in the laboratory of Prof. Cheryl Nickerson at the Biodesign
1941 Institute at Arizona State University. She then received a postdoctoral position in the Nickerson
1942 lab, where she developed and used physiologically relevant models of the lung mucosa to
1943 explore host-pathogen interactions. She is currently a team leader in the Laboratory of
1944 Pharmaceutical Microbiology at Ghent University under the tutelage of Prof. Tom Coenye,
1945 through an Odysseus fellowship of the Research Foundation Flanders. Her research focuses on
1946 understanding how the host, microbiome and their interactions influence antimicrobial agent
1947 efficacy and inflammation in chronic lung infections. To this end, *in vivo*-like models of lung
1948 epithelium, the microbiome or both are used, to facilitate translation of *in vitro* results to novel
1949 therapeutic approaches.
1950
1951
1952 **Jiseon Yang** is an Alfred P. Sloan postdoctoral fellow (NASA joint program) at the Biodesign
1953 Institute, Arizona State University/ASU. She received her M.S. in Microbiology studying
1954 *Salmonella* pathogenesis from Pusan National University(South Korea). She subsequently
1955 worked with Dr. Roy Curtiss III and Dr. Josephine Clark-Curtiss(ASU) on developing a
1956 2nd generation lysis system in recombinant attenuated *Salmonella* vaccines to deliver
1957 *Mycobacterium tuberculosis* antigens. She received her Ph.D. in Microbiology under Dr. Cheryl
1958 Nickerson(ASU), where she characterized virulence, stress and molecular genetic responses of
1959 invasive, multidrug-resistant nontyphoidal *Salmonella* to physiological fluid shear. She was co-
1960 first author on the first report of an RWV-derived 3-D intestinal co-culture model (epithelial cells,
1961 macrophages) to study *Salmonella* pathogenesis. She currently studies how microbes inhabiting
1962 built environments influence human health and systems integrity using the International Space
1963 Station as a microbial observatory to reveal new insight into how interspecies interactions within
1964 microbial populations can adapt/evolve over time.
1965
1966
1967 **Karla Franco** received her Bachelor's degree in General Science from Pontificia Universidad
1968 Catolica de Puerto Rico. She became interested in microbial pathogenesis during a year-long
1969 NIH training fellowship (ASU PREP). She enrolled in the Microbiology Ph.D. Program at Arizona
1970 State University, where she received a two year fellowship from the NIH IMSD program. As a

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest
Infection and Immunity

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

1971 member of the Nickerson laboratory, she has spent the last three years investigating the role of
1972 mechanotransduction in regulating the phenotypic and molecular genetic responses of
1973 *Salmonella* Typhimurium.
1974
1975
1976 **Seth D. Nydam** received his doctorate in veterinary medicine from Cornell University and his
1977 Ph.D. from Washington State University. His graduate studies in Dr. Douglas Call's laboratory
1978 centered on the type III secretion system of *Vibrio parahaemolyticus*, after which he joined Dr.
1979 Cheryl Nickerson at Arizona State University for postdoctoral training to explore 3-D cell culture
1980 and its interactions with resident microflora and *Salmonella* pathogenesis. He is currently the
1981 clinical veterinarian at Arizona State University's Department of Animal Care and Technologies,
1982 where he leads the clinical team and provides research support and oversight. His continuing
1983 interests include microbial pathogenesis, animal models in infectious disease research, and
1984 teaching.
1985
1986
1987 **Rebecca J. Forsyth** received her B.S. in Microbiology from Arizona State University in 2008.
1988 She first joined the Nickerson laboratory as an undergraduate student, was subsequently hired
1989 as an Assistant Research Technologist and was later promoted to the positions of Associate
1990 Research Specialist and Senior Research Specialist. She used a variety of 3-D models,
1991 microbes and model host organisms in her infectious disease research. She was passionate
1992 about using "outside-of-the-box" approaches to solve important biomedical health issues,
1993 including the use of the spaceflight platform and the RWV bioreactor to study microbial
1994 physiology and host-pathogen interactions.
1995
1996
1997 **Richard R. Davis** is a Senior Research Specialist in the Biodesign Center for Immunotherapy,
1998 Vaccines, and Virotherapy at Arizona State University. He earned his B.A. in Anthropology in
1999 2001 and a B.S. in Microbiology in 2007 from Arizona State University. He joined the Nickerson
2000 laboratory as an undergraduate student, was subsequently hired as an Assistant Research
2001 Technician and was later promoted to the positions of Research Specialist and Senior Research
2002 Specialist. His research over the past eleven years has focused on using both the microgravity
2003 platform (including six spaceflight experiments) and the RWV bioreactor to study the effect of
2004 physical forces on microbial pathogenesis and host-pathogen interactions.
2005
2006
2007 **Sandhya Gangaraju** received her Master's degree in Biochemistry in 2003 from the University
2008 of Ottawa, Canada. In 2003, she joined the National Research Council, Canada as a research
2009 technical officer and viral facility manager in the department of neurogenesis and brain repair.
2010 She implemented lentiviral technology to deliver neurotropic factors to neural cells and
2011 developed transwell assays to study neutrophil transmigration through endothelial cells. In 2014,
2012 she joined the Biodesign Institute, Arizona State University as a principal research specialist
2013 and compliance officer for the Center for Biosignatures Discovery Automation, where she
2014 managed the cell culture facility, lead experimental design for students and junior staff
2015 members, and optimized working protocols for microfluidic devices for studying three-
2016 dimensional tissue environments. Most recently, she joined the Nickerson laboratory as a
2017 principal research specialist where she uses the RWV and the spaceflight platform to study
2018 microbial pathogenesis and for 3-D tissue engineering.
2019
2020

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online

Infection and Immunity

IAI

Infection and Immunity

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

2021 **C. Mark Ott** received his B.S. in Chemical Engineering from the University of Texas at Austin in
2022 1982, his M.B.A. from Louisiana State University in 1989, and his Ph.D. in Microbiology from
2023 Louisiana State University in 1998. He has published extensively in the areas of microbial
2024 ecology in spacecraft, human and microbial responses to spaceflight, and the development of
2025 advanced tissue culture models to investigate infectious disease. For the past 20 years, Dr. Ott
2026 has served as a technical lead in the Johnson Space Center Microbiology Laboratory, which is
2027 responsible for mitigating infectious disease risk during human spaceflight. His responsibilities
2028 include the assessment of microbial risk and development of spaceflight requirements based on
2029 vehicle and mission architecture as well as crewmember, food, and environmental monitoring.
2030
2031
2032 **Carolyn Coyne** completed her Ph.D. at the University of North Carolina at Chapel Hill, USA,
2033 where she studied the human respiratory epithelium. She then carried out her postdoctoral
2034 fellowship at the Children's Hospital of Philadelphia (CHOP), Pennsylvania, USA, and the
2035 University of Pennsylvania, Philadelphia, USA, where her research focused on identifying the
2036 mechanisms by which enteroviruses invade the gastrointestinal epithelium and blood–brain
2037 barrier endothelium. She joined the University of Pittsburgh, Pennsylvania, USA, as a faculty
2038 member in 2007, where her work continued to focus on defining the mechanisms by which
2039 viruses breach cellular barriers. Dr. Coyne's laboratory also studies how the human placenta
2040 restricts viral infections. Her research interests also include the development of primary—and
2041 cell line-based models of cellular barriers, focusing on both the GI tract and placenta. Her
2042 research interests include enteroviruses and flaviviruses, with a particular emphasis on the
2043 strategies by which these viruses bypass cellular barriers.
2044
2045
2046 **Mina J. Bissell** is Distinguished Scientist, the highest rank bestowed at Lawrence Berkeley
2047 National Laboratory and serves as Senior Advisor to the Laboratory Director on Biology. She is
2048 also Faculty of four Graduate Groups in UC Berkeley: Comparative Biochemistry,
2049 Endocrinology, Molecular Toxicology, and Bioengineering (UCSF/UCB joint). Having challenged
2050 several established paradigms, Bissell is a pioneer in breast cancer research and her body of
2051 work has provided much impetus for the current recognition of the significant role that
2052 extracellular matrix signaling and microenvironment play in gene expression regulation in both
2053 normal and malignant cells. Her laboratory developed novel 3D assays and techniques that
2054 demonstrate her signature phrase: after conception, "phenotype is dominant over genotype."
2055 Bissell has received numerous honors and awards and is an elected Fellow of most U.S.
2056 honorary scientific academies. She has published over 400 publications and continues to
2057 engage in full-time research, among other scientific activities.
2058
2059
2060 **Dr. Cheryl A. Nickerson** is a Professor in the School of Life Sciences at the Biodesign Institute,
2061 Arizona State University. She received her Ph.D. in Microbiology from Louisiana State
2062 University. Her postdoctoral training in *Salmonella* pathogenesis was done with Dr. Roy Curtiss
2063 III at Washington University in St. Louis. She initiated her ongoing studies into the connection
2064 between cellular biomechanics/mechanotransduction and host-pathogen systems biology after
2065 joining the faculty at the Tulane University School of Medicine in 1998. Her development of
2066 innovative model pathogenesis systems includes 3-D organotypic tissue culture models to study
2067 host-pathogen interactions, and approaches that characterize pathogen responses to
2068 physiological fluid shear forces encountered in the infected host, and in the microgravity
2069 environment of spaceflight. She received the Presidential Early Career Award for Scientists and
2070 Engineers, NASA's Exceptional Scientific Achievement Medal, is an American Society for
2071 Microbiology Distinguished Lecturer, and was selected as a NASA Astronaut candidate finalist.

2072

Infection and Immunity

IAI

Infection and Immunity

Accepted Manuscript Posted Online

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest

Accepted Manuscript Posted Online
Infection and Immunity
IAI
Infection and Immunity



B

RWV Bioreactor	Organoid Culture	Organ-on-a-Chip
a	b	c
d	e	f
g	h	i

Downloaded from http://iai.asm.org/ on September 26, 2018 by guest